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ABSTRACT 
 
Type 2 diabetes is one of the diseases that largely determined by lifestyle factors. Coffee is 
one of the most consumed beverages in the world and recently released data suggest the 
effects of coffee consumption on type 2 diabetes. The objective of the present study was to 
evaluate the effects of habitual coffee consumption on various aspects of type 2 diabetes 
and its most common complications.   
 
This study is part of the national FINRISK studies. Baseline surveys were carried out 
between 1972 and 1997. The surveys covered two eastern regions in 1972 and 1977, but 
were expanded to include a third region in southwestern Finland in 1982, 1987, 1992, and 
1997. The Helsinki capital area was included in the survey in 1992 and 1997 and the Oulu 
province, in northern Finland, in 1997. Each survey was drawn from an independent 
random sample of the national register of subjects aged 25-64. In 1997, an additional 
sample of subjects aged 65-74 was conducted.  
   
The blood pressure, weight, and height of subjects were measured. By using self-
administered questionnaires data were collected on medical history, socioeconomic factors, 
physical activity, smoking habits, and alcohol, coffee, and tea consumption.  
 
Higher coffee consumption was associated with higher body mass index, occupational 
physical activity and cigarette smoking, and lower blood pressure, education level, leisure 
time physical activity, tea consumption and alcohol use.  
Age, body mass index, systolic blood pressure and current smoking were positively 
associated with the risk of type 2 diabetes, however, education, and occupational, 
commuting and leisure time physical activity were inversely associated.  
 
The significant inverse association between coffee consumption and the risk of type 2 
diabetes was found in both sexes but the association was stronger in women. Coffee 
consumption was significantly and inversely associated with fasting glucose, 2-hour plasma 
glucose, fasting insulin, impaired fasting glucose, impaired glucose regulation, and 
hyperinsulinemia among both men and women and with isolated impaired glucose 
tolerance among women.  
 
Serum γ-glutamyltransferase modified the association between coffee consumption and incident 
diabetes. Among subjects with high serum γ-glutamyltransferase (>75th percentile), coffee 
consumption showed an inverse association for women, as well as men and women combined.  
 An inverse association also occurred between coffee consumption and the risk of total, 
cardiovascular disease, and coronary heart disease mortality among patients with type 2 diabetes.  
 
The results of this study showed that habitual coffee consumption may be associated with a 
reduced risk of type 2 diabetes. Coffee consumption may have some effects on several markers 
of glycemia, and may lower the incident of type 2 diabetes in high normal serum γ-glutamyl-
transferase levels. Total, cardiovascular disease, and coronary heart disease mortality rate 
among subjects with type 2 diabetes may also be reduced by coffee consumption. 
 
 
Keywords: Coffee, Diabetes mellitus type 2, Risk factors, Cardiovascular diseases, 
Coronary disease, Health surveys 
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1. INTRODUCTION 
 
 
There is no doubt that coffee is one of the most desired and consumed beverages in the world and 
Finns seems to partake the most with 11.6 kg per capita, while the European average is 5 kg 
(Figure 1) (International Coffee Organization (ICO) 2007). Why did coffee become so popular, 
and fulfill a “progressive” social function? The most probable answer might be in the rapid 
prominent stimulant effect of coffee for increasing alertness; even the actual aroma and smell of 
fresh brewed coffee would be enough to start stimulation in coffee drinkers!   
Average coffee consumption per capita 2001-2005
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Figure 1. Average coffee consumption based on the data from ICO. 
 
During the recent decades, research has attempted to evaluate the harms or benefits received from 
coffee. Knowledge on both the positive and negative health effects of coffee is important; it 
allows individuals to make informed choices regarding coffee consumption. The potential health 
effects of coffee and caffeine have been studied through epidemiological, clinical, and 
experimental research. The psychoactive effects of caffeine have been well documented, and the 
effects of coffee are considered synonymous with those of caffeine. Even though other, more 
abundant components of coffee, may also have many biological effects but may have not yet 
been extensively studied.  
  
In fact, coffee is a complex mixture of potential physiologically active chemicals. Coffee's 
chemical composition is determined by a complex interaction of agricultural factors, roasting, 
blending, and brewing. Other than caffeine, coffee is the major source of phenolic polymers and 
chlorogenic acid (Clifford 2000; Herrmann et al. 1976; Kuhnau  1976) which is believed to 
possess antioxidant activity and possibly useful in healing or preventing diseases. The most 
prevalent phenolic compounds in food are hydroxycinnamic acids (Manach 2003; Herrmann et 
al. 1976; Kuhnau 1976). A major component of this class is caffeic acid, which occurs in food 
mainly as esters called chlorogenic acid (Clifford 2000). Although compounds with antioxidant 
properties (mainly chlorogenic acid) are lost during the roasting of coffee beans (Parliament et al. 
2000), the overall antioxidant activities of coffee brews can be maintained, or even enhanced, by 
the development of compounds possessing antioxidant activity (Shearer et al. 2003).  
 
 
Type 2 diabetes is the most common form of diabetes and a major health problem, associated 
with excess morbidity and mortality, resulting in substantial health care costs. It is caused by a 
complicated interplay between genes and environment. The environmental factor such as obesity 
is an absolute risk for developing type 2 diabetes, but many obese individuals are not diabetic and 
many type 2 diabetes cases occur among non-obese people. It demonstrates that genetic factors 
may play an important role in developing type 2 diabetes, but the pattern might be complicated, 
involving multiple genes and multiple gene-environment interactions. 
 
 
Type 2 diabetes is a progressive, life-long condition that increases the risk for many serious 
complications such as cardiovascular disease, retinopathy, neuropathy, and nephropathy. This 
chronic condition is characterized by the development of both microvascular and macrovascular 
complications. These complications, accounts for most of the increased morbidity and mortality 
associated with type 2 diabetes (Kannel and McGee 1997; Nathan  1993; Stamler et al. 1993; 
Manson et al. 1991; Fuller et al. 1983). The costs of diabetes care are mostly attributed to the long 
term complications. New guidelines however have revealed that changing the lifestyle and dietary 
behavior can prevent, or delay, the development of the disease and its complications as well.   
 
 
This study describes the association of habitual coffee consumption with developing type 2 
diabetes among individuals in Finland. The study examined the association between coffee 
consumption and different parameters of glucose metabolism. The interaction between serum 
γ-glutamyltransferase (GGT) and coffee consumption on the risk of type 2 diabetes has been 
assessed and the effects of coffee consumption on the risk of total and cardiovascular disease 
(CVD) mortality among patients with type 2 diabetes has also been evaluated. 
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 2.      REVIEW OF THE LITERATURE 
2.1      Definitions and classification of type 2 diabetes 
 
Appropriate classification is major requirement for orderly epidemiologic and clinical research on 
and management of diabetes mellitus. Furthermore, a hallmark in the process of understanding 
the etiology of a disease and studying its natural history is the ability to identify and differentiate 
its various forms and place them into a rational etiopathologic framework. While a number of 
nomenclature and diagnostic criteria have been proposed for diabetes, no systematic 
categorization existed until just two decades ago. Now diabetes mellitus is recognized as being a 
syndrome, a collection of disorders that have hyperglycemia and glucose intolerance as their 
hallmark, due to either insulin deficiency or to the impaired effectiveness of insulin’s action, or a 
combination of these.  
 
 
Type 2 diabetes, formerly known as non-insulin-dependent diabetes, is the most common form of 
diabetes and a major health problem associated with excess morbidity and mortality and results in 
substantial health care costs. In western countries, it constitutes approximately 90% of all 
diabetes cases. In certain populations such as North American Indians and in the South Pacific 
regions, it is virtually the only form of diabetes (Zimmet et al. 1990). The total number of people 
with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 (Wild et al. 
2004). In Europe, their number will increase from approximately 16 million in 1994 to 24 million 
in 2010 (Amos et al. 1997). 
 
In contrast to Type 1 diabetes or insulin dependent diabetes mellitus, patients with type 2 diabetes 
are not dependent on exogenous insulin for the prevention of ketonuria. They may, however, 
require insulin for the correction of hyperglycemia if this cannot be achieved through diet or oral 
anti diabetic agents. Most patients diagnosed with type 2 diabetes are adults, but the disease may 
also occur in young people not requiring insulin. In addition, the age at diagnosis of type 2 
diabetes tends to be much younger in high prevalence groups (French et al. 1990). Consequently, 
age at onset is not recommended as a determinant of whether a patient should be classified as 
type 2 diabetic and the terms “adult-onset” and “maturity-onset” diabetes are no longer in use.  
 
 
Type 2 diabetes is caused by a complicated interplay between genes and environment. Genetic 
factors play an important role in type 2 diabetes, but the pattern is complicated, since both 
impairment of beta cell function and abnormal response to insulin are involved.  
During the past decade, plenty of efforts have been devoted to exploring type 2 diabetes genes. 
These genes encode proteins strongly linked to diabetes (Sandhu et al. 2007; Winckler et al. 
2007; Gudmundsson et al. 2007; Florez et al. 2004;Nielsen et al. 2003; Gloyn et al 2003; 
Altshuler et al. 2000; Horikawa et al. 2000). For instance, defective genes that regulate a 
molecule called peroxisome proliferator-activated receptor gamma (PPARγ) may contribute to 
type 2 diabetes in some patients. It regulates adipocyte differentiation and lipid and glucose 
metabolism (Altshuler et al. 2000; Auwerx 1999). Geneticists have also identified genes that 
13
 were mutated in diabetic patients (Gloyn et al. 2004; Barroso et al. 1999; Nishigori et al. 1998; 
Inoue et al. 1998) and genes that are targets of anti diabetic therapies (Nielsen et al. 2003; 
Altshuler et al. 2000).  
A strong genetic basis of the disease is evidenced by the frequent familial pattern of occurrence, 
its high prevalence in certain ethnic groups, and genetic admixture studies. Studies on identical 
twins have been particularly important in establishing the influence of genetic factors in the 
etiology of type 2 diabetes. Most of the co-twins of people with type 2 diabetes develop the 
disease themselves, but discordance indicates that environmental factors are also involved in the 
etiology (Kaprio et al. 1992; Newman et al. 1987). A large Finnish twin cohort study found the 
heritability of type 2 diabetes to be about 79% (Kaprio et al. 1992).  
Dramatic changes in the prevalence or incidence of type 2 diabetes have been observed in 
communities where major changes have occurred in the type of diet consumed, from a traditional 
indigenous diet to a typical western diet, e.g. Pima Indians in Arizona, Micronesians in Nauru 
and Aborigines in Australia (Lako et al. 2001; Bennett 1999; Hetzel and Michael 1987).  
Changing disease rates are almost explained by changes in several dietary factors as well as by 
changes in other lifestyle related factors (obesity and sedentary lifestyle). This may be 
particularly important in triggering the genetic elements that cause this type of diabetes.  
 
 
Type 2 diabetes is characterized by the progressive development of the microvascular and 
macrovascular complications. These complications, and in particular atherosclerotic lesions, are 
the main causes for most of the increased morbidity and mortality in type 2 diabetes and the 
people with the disease are at much higher risk of fatal ischemic heart disease and stroke (Kannel 
and McGee 1997; Nathan 1993; Stamler et al 1993; Manson et al. 1991; Fuller et al. 1983).  
In general, type 2 diabetes increases the risk of CVD mortality to about 3-fold compared with 
non-diabetic subjects. The progression of atherosclerosis in diabetes is probably the result of the 
other major risk factors which are more prevalent in diabetics. Obesity and dyslipidemia, the 
derangement in carbohydrate metabolism (hyperglycemic environment, hyperinsulinism, and 
insulin resistance), a prothrombotic tendency, microalbuminuria, and hypertension are some of 
these factors (Stevense et al. 2004; Knight 2003; Pastor-Barriuso et al. 2003; Resnick and 
Howard 2002; Tooke 2000; Harris and Eastman 1998). The costs of diabetes care are mostly 
attributed to the long term complications. 
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2.2        Coffee 
 
The word coffee is derived from the name of the province Keffa where, prior to 1000 A.D., 
goatherds from Abyssina/Ethiopia discovered the strange effect of wild coffee beans on the goats. 
 
Seven centuries after this accidental discovery, coffee’s restorative power was well known and 
coffee spread throughout the neighboring countries, mostly Arabic Islamic countries. About 200 
years later coffee entered to the Europeans life and was thoroughly accepted as a new beverage 
(National Geographic Society 1999). Now, coffee is one of the most consumed beverages in the 
world and while a great number of its constituents have been recognized, a better understanding 
of their actual effects on human health and metabolism is greatly desired.   
 
 
 
 
 
 2.2.1     Chemical Composition of Coffee  
 
Although coffee has been consumed for centuries, the chemical composition of coffee is not 
completely known. Coffee is a complex mixture of more than a thousand chemical components 
determined by a complex interaction of agricultural factors, roasting, blending, and brewing. The 
water soluble constituents are: phenolic polymers (pulp) 8%, polysaccharides 6%, chlorogenic 
acids 4%, minerals 3%, water 2%, caffeine 1%, organic acids 0.5%, sugars 0.3%, lipids 0.2%, 
and aroma 0.1% (Institute for Coffee Studies 2001).  
According to phytochemical database (Agricultural Research Service 2007), unroasted, green 
coffee seeds contain the following soluble compounds: 
 
2,3,5-TRIMETHYLPHENOL,  
2-ETHYLPHENOL 
 2-METHOXY-4-ETHYLPHENOL 
 2,4-METHYLENEPHENOL 
DICAFFEOYL-QUINIC ACID 
4-ETHYLPHENOL 
4-METHOXY-4-VINYLPHENOL 
ACETALDEHYDE 
CAFFEINE 
CAFFEOL 
CAFFEOYL-3-QUINIC ACID 
CAFFETANNIC ACID 
CHLOROGENIC ACID 
CITRIC ACID 
DATURIC ACID 
GUAIACOL 
HYPOXANTHINE 
ISOCHLOROGENIC ACID 
PUTRESCINE 
SCOPOLETIN 
SPERMIDINE 
SPERMINE 
SUGARS 
TANNIC ACID 
TANNIN 
THEOBROMINE 
THEOPHYLLINE 
THIAMIN 
TRIGONELLINE 
XANTHINE 
16
 Some of the coffee’s compounds are more involved in human health and/or better documented in 
previous literature. Caffeine and chlorogenic acid are two of them.  
 
 
Caffeine  
  
Caffeine or 1,3,7-trimethylxanthine is a natural purine alkaloid in coffee beans. It is probably the 
most frequently ingested pharmacologically active substance in the world (Nawrot et al. 2003). 
After the ingestion of caffeine, it is rapidly and almost completely absorbed in the stomach and 
early parts of the intestine, and then distributed to all parts of body. Caffeine metabolism takes 
place in the liver by cytochrome P450 isoform (CYP1A2). Almost 95% of caffeine is metabolized 
through this pathway resulting in the formation of 1,7-dimethylxanthine (paraxanthine). The final 
product of destabilization will be 5-acetylamino-6-amino-3-methyluracil (figure 1) (Crews et al. 
2001; Krul and Hageman 1998). 
 
Caffeine appears to exert its biological effects through the antagonism of the adenosine receptors 
(figure 2). Some known physiological effects, which mostly appear early after administration, 
include the stimulation of the central nervous system, raised blood pressure, metabolic rate 
elevation, and diuresis. The concentration of the caffeine in various coffee beverages is quite 
17
 different, even among a particular population. It has been assumed that a cup of coffee (240 ml) 
should contain 100 mg of caffeine, however, a recent study in the US revealed that the amount of 
the caffeine in a cup of brewed coffee (240 ml), prepared at different coffee shops ranged from 
70 to 130 mg (McCusker 2003). Therefore, various preparation methods of coffee in different 
societies may cause a wide range of caffeine concentration.     
   
Chlorogenic acid 
 
Green coffee beans contain significant amount of chlorogenic acids, i.e. various isomers of 
hydroxy-cinnamoyl esters of quinic acid (a common plant constituent). Common to most plants 
and fruits, green coffee beans can contain as much as 10% of their dry weight of chlorogenic 
acids. These are mixtures of mono- and di-esters of 3-substituted 4-hydroxycinnamic acid and 
quinic acid, a sugar-like molecule. Approximately half of the chlorogenic acids lose a molecule 
of water in the roasting process, thereby forming an internal ester bond that results in a mixture of 
non-acidic quinolactones (quinides) (Hucke and Maier 1985). Brewing roasted coffee causes the 
isomerization of the quinides. This results in hundreds of different compounds, each with 
potentially unique pharmacological actions. Although few of these compounds are present at 
more than 0.3% of the dry weight of coffee, they still may significantly contributed to the effects 
of the coffee since these compounds have chemical properties that allow ready entry into the 
18
 brain (Olthof  et al. 2001). Furthermore, the synergistic effects of different quinides acting on the 
same biological target may contribute to the health effects of coffee. For coffee drinkers, coffee is 
the richest dietary source of chlorogenic acids and cinamic acids (caffeic acid). A cup of coffee of 
200 ml, contains 70 to 350 mg of chlorogenic acid and 35 to 175 mg of caffeic acid.  
Intestine absorbs 95% of caffeic acid and 33% of chlorogenic acid. The remaining chlorogenic 
acid reaches the colon where it may be hydrolyzed to caffeic acid and quinic acid (Olthof et al. 
2003; de Paulis et al. 2002; Olthof et al. 2001; Clifford 1999) (figure 3).   
 
Micronutrients 
 
Some micronutrients found in coffee include magnesium, potassium, vitamin E, and niacin. They 
may contribute to the observed positive effects of coffee. The amount of the magnesium in a cup 
of coffee (240 ml) is 1 to 5% of the daily allowance (420 mg/d) and potassium intake is only 1 to 
2% (4700 mg/d). Nicotinic acid is a transverse form of trigenolline in coffee beans and a cup of 
coffee provide 1 to 3 mg per cup and 6 to 18% of daily allowance for niacin (16 mg/d) (U.S. 
Department of Agriculture and Agricultural Research Service 2004; Institute of Medicine 2004; 
Institute of Medicine 1997; Institute of Medicine 1998; Adrian and Frangne 1991). Coffee is not 
a good source of vitamin E since a cup of coffee contains about 0.2 mg of α-tocopherol and 0.2 
mg γ-tocopherol, only 0.1% of daily requirement for vitamin E (Institute of Medicine 2000; U.S. 
Department of Agriculture and Agricultural Research Service 1997).   
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 2.2.2      Coffee and its impact on Human Health 
 
Since a great number of people around the world drink coffee, a great concern exists regarding 
the possible role of coffee on human and public health, since small effects in people could have a 
large impact on public health. During the last decades, researchers attempted to evaluate health 
benefits, or harms, received from coffee drinking. Knowledge of both positive and negative 
health effects of coffee is important to allow individuals to make informed choices regarding 
coffee consumption. The associations between coffee and caffeine, the fame compound of coffee, 
with common chronic diseases have been examined through epidemiological, clinical, or 
experimental research.  
 
Coffee and Parkinson’s disease The association between coffee consumption and Parkinson’s 
disease has been evaluated in the wide range of studies. Overall, the results of the case-control 
studies revealed that coffee and caffeine ingestion are inversely associated with the risk of 
Parkinson’s disease (Hernan et al. 2002). The results from prospective studies are inconsistent. 
The risk of Parkinson’s disease is markedly reduced among men but not women (Ascherio et al 
2004; Ascherio et al. 2001; Ross et al. 2000), however, two recent studies from Finland found an 
inverse association in both men and women (Sääksjärvi et al. 2007; Hu et al. 2007).  
 
Coffee and Cancer Although previous studies, particularly case-control studies, revealed a 
positive association between coffee and caffeine intake and bladder, ovarian and pancreatic 
cancers (Zeegers et al. 2001; D'Avanzo et al 1992; Miller et al. 1987), more recent and better 
designed studies have not confirmed them. Overall recent prospective cohort studies have not 
observed significant association between coffee consumption or caffeine intake and the risk of 
the bladder, ovarian, breast, gastric, pancreatic and prostate cancer (Zeegers 2004; Nawrot et al. 
2003; Tavani and La Vecchia 2000; Leviton 1990). 
 
 
2.2.2.1     Coffee, Glucose Tolerance and Insulin Sensitivity 
 
Most of the controlled clinical trials have revealed that acute administration of caffeine will 
impair glucose tolerance and insulin sensitivity (Petrie et al. 2004; Keijzers et al. 2002; Graham 
et al. 2001; Greer F 2001). Using the hyperinsulinemic-euglycemic glucose clamp method, 
Keijzers et al. found that caffeine decreased insulin sensitivity by 15% (P< 0.05 for trend vs. 
placebo) in12 healthy volunteers (Keijzers et al. 2002). In another study, 18 young adult men first 
ingested caffeine (5 mg/kg) or placebo followed one hour later by 75 g of dextrose [oral glucose 
tolerance test (OGGT)]. Caffeine ingestion resulted in an increase in serum insulin, C peptide and 
blood glucose for the duration of the OGTT (P< 0.05 for trend). This suggests that caffeine 
ingestion may have resulted in insulin resistance (Graham et al. 2001).  
Greer et al., investigated glucose disposal following administration of caffeine. Nine healthy, 
lean, sedentary men underwent two trial sessions one with caffeine (5 mg/kg body wt) and one 
with placebo (dextrose) administration. Glucose disposal was assessed using the 
20
 hyperinsulinemic-euglycemic clamp. Caffeine administration resulted in a significant decrease 
(24%) in glucose disposal compared to the placebo (Greer et al. 2001).  
 
The effects of coffee consumption over a period of 2 to 4 weeks on serum glucose and insulin level 
have been examined in a randomized clinical trial. Drinking decaffeinated coffee for 14 days, by 
prior consumers of an average of 560 mg/d of caffeine from coffee or tea, caused fasting blood 
glucose level to decrease significantly (Naismith et al. 1970).  
Two recent crossover trial studies, examined the effects of coffee and caffeine on fasting blood 
glucose and insulin levels. In the first study, participants, who were regular coffee consumers of 
five to eight cups per day, were randomly assigned to drink one liter filtered coffee containing 1100 
mg of caffeine for four weeks and then four weeks abstention. They found a higher fasting insulin 
level, but no effects on the fasting glucose level after coffee period compared to abstention. The 
second crossover study, which examined participants consuming a weaker caffeine, regular paper 
filtered coffee, or placebo, found similar fasting glucose concentrations and a nonsignificant 
association with higher fasting insulin concentrations (van Dam et al. 2004a).  
 
Battram et al. compared the acute effects of caffeine or coffee ingestion on glucose metabolism and 
found impaired glucose tolerance following both. While caffeine ingestion resulted in higher glucose, 
insulin, and C peptide responses compared to both placebo and decaffeinated coffee, regular coffee 
consumption only resulted in an attenuated response for glucose and insulin when compared with 
decaffeinated coffee, but no difference compared to the placebo (Battram et al. 2006). 
  
Although most of the short term trials of coffee and caffeine ingestion demonstrate the negative 
impacts on glucose tolerance and insulin sensitivity, epidemiological studies reveal that chronic 
consumption of coffee may help to maintain normal glucose tolerance.  
Cross-sectional studies from diverse countries have found that coffee consumption is inversely 
associated with the prevalence of impaired glucose tolerance after oral glucose load (Yamaji et al 
2004; Soriguer et al. 2004; Agardh et al. 2004).  
For instance, Yamaji et al performed a cross-sectional study of 3224 males to investigate the 
relationship between coffee consumption and glucose tolerance. A total of 1130 men were 
identified as having glucose intolerance. Fasting and 2-h post-load plasma glucose level were 
1.5% and 4.3% lower in those who drank five cups of coffee or more per day compared to those 
who did not drink coffee. Thus they concluded that coffee may help to prevent postprandial 
hyperglycemia (Yamaji T et al 2004).  
Another cross-sectional study comprised 7949 healthy Swedish subjects aged 35-56. An oral 
glucose tolerance test identified 107 participants with previously undiagnosed type 2 diabetes and 
339 participants with impaired glucose tolerance. The relative risks of type 2 diabetes and 
impaired glucose tolerance in those drinking five cups of coffee or more per day compared with 
two cups or less per day in men were 0.45 (95% CI 0.22-0.92) and 0.63 (95% CI, 0.41-0.97) and 
in women 0.27 (95% CI 0.11-0.66) and 0.47 (95% CI 0.27-0.76). High coffee consumption (>5 
cups/day) was inversely associated with insulin resistance in those subjects with type 2 diabetes 
and impaired glucose tolerance.  
The recently published results of the cohort studies are consistent with these cross-sectional 
studies. A prospective cohort study of Dutch men and women found an inverse association 
between habitual coffee consumption and the risk of developing impaired glucose tolerance 
(OR=0.37, 95% CI 0.16–0.84 for 7 vs. 2cups per day). No association between coffee 
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 consumption and impaired fasting glucose emerged (OR=1.35, 95%CI, 0.80–2.27 for 7 vs. 2 
cups per day), which may be interpreted as coffee consumption affects post-load glucose 
metabolism more than fast glucose (van Dam et al. 2004b). In addition, another prospective study 
from the U.S. investigated the association between coffee consumption and incident diabetes 
based on the OGGT and examined coffee habits in those with impaired glucose separately from 
those with normal glucose. They found that current or past coffee drinkers had a 60% reduced 
risk of type 2 diabetes compared with those who never drank coffee (past vs. never, OR=0.38, 
95% CI, 0.17-0.87, current vs. never OR=0.36, 95% CI, 0.19-0.68). In addition, those who had 
impaired glucose at the baseline were similarly protected against incident diabetes (past vs. never, 
OR=0.31 95% CI, 0.11-0.87, current vs. never OR=0.36, 95% CI, 0.16-0.83) (Smith et al. 2006). 
 
 
2.2.2.2     Coffee and Type 2 Diabetes 
 
Although various health effects of coffee have been extensively investigated until recently the 
association of coffee consumption and development of type 2 diabetes has not been thoroughly 
studied.  
A prospective study of about 17,000 Dutch men and women found that the risk of developing 
type 2 diabetes was 50% lower in those who drank seven cups of coffee daily compared to those 
who drank two cups or less (95% CI, 0.35-0.72) (van Dam and Feskens 2002).  
Two large prospective cohort studies, the U.S. Health Professional Follow-up Study including 
41,934 men and the Nurses’ Health Study including more than 84,000 women, revealed that in 
men who drank at least six cups of coffee daily the risk of developing type 2 diabetes is 54% less 
than men who abstain from coffee abstainers (95% CI, 0.26-0.82). Among women with the same 
amount of coffee consumption they observed a 29% lower risk in habitual coffee consumers 
compared to coffee abstainers (95% CI, 0.56-0.89) (Salazar-Martinez E 2004). A moderate 
inverse association was also observed between decaffeinated coffee and the risk of type 2 
diabetes in those cohorts.  
 
In a study on the Finnish twin cohort, there was a 35% risk reduction (95% CI, 0.44-0.96) among 
those who drank seven cups of coffee or more compared with those who drank two cups or less 
(Carlsson 2004).  
In another cohort of Swedish women, those who drank three cups of coffee had a 50% lower  risk 
of type 2 diabetes than those who drank two cups or less (95% CI, 0.22-1.06) (Rosengren 2004). 
Another community-based cohort from the U.S, which examined the effect of coffee and 
sweetened beverage consumption on the risk of type 2 diabetes, showed the same inverse 
association in these community-based U.S. African American and Caucasian adults with a 23% 
decreased risk (95% CI, 0.61-0.98) in men and 33% (95% CI, 0.45-0.96) in women compared to 
abstainers (Paynter et al. 2006).  
An 11-year prospective study of about 29,000 postmenopausal women found an inverse 
association between coffee consumption and the risk of type 2 diabetes, particularly in 
decaffeinated coffee consumers (RR=0.79, 95% CI, 0.50-0.88) (Pereira MA et al. 2006). The 
Nurses’ Health Study II, which included 88,259 U.S. women aged 26-46, evaluated the 
association between coffee and caffeine and the risk of type 2 diabetes.  The relative risk of type 
2 diabetes was reported as 0.87 (95% CI, 0.73-1.03) for one cup/day, 0.58 (95% CI, 0.49-0.68) 
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 for 2-3 cups/day, and 0.53 (95% CI 0.41-0.68) for four or more cups of coffee per day compared 
to non-drinkers (P <0.0001 for trend). This study indicated an inverse association of both 
caffeinated and decaffeinated coffee with the risk of type 2 diabetes (van Dam et al. 2006).  
Also, in a recently published Japanese study, including 17,413 people, the risk of type 2 diabetes 
for those who drank three or more cups of coffee daily was 42% lower than those who drank 1 
cup or less per week (RR=0.58, 95% CI, 0.37-0.90) (Iso et al. 2006). Table 1 summarizes the 
results of the 14 prospective cohort studies on coffee consumption and the risk of type 2 diabetes. 
 
Not all recent data were observed as an inverse association between the coffee consumption and 
type 2 diabetes. In fact an earlier Finnish cohort study of more than 19,000 men and women 
(1973-1977), with an average follow-up of 14 years, found a positive association between coffee 
consumption and type 2 diabetes (Reunanen et al. 2003). Also, a study of Pima Indians found no 
association between the coffee consumption and the risk of type 2 diabetes (Saremi et al. 2003).  
 
A systematic review of about nine cohort studies revealed that the risk of developing type 2 
diabetes in participants who drank four to six cups or more than six to seven cups of coffee per 
day to be 28% and 35% lower than those who drank less than two cups daily. They found the 
same inverse association between coffee consumption and impaired glucose tolerance or type 2 
diabetes in cross-sectional studies (van Dam and Hu  2005). 
 
Overall, the results of this brief review of the literature supports the hypothesis that habitual 
coffee consumption may be associated with a substantially lower risk of type 2 diabetes and 
glucose intolerance in both men and women.      
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 3.  AIMS OF THE STUDY 
 
 
The first aim of this study was to determine the relationship between coffee consumption and the 
incidence of type 2 diabetes among middle aged Finnish men and women and to examine joint 
associations of coffee consumption and other factors (including physical activity, obesity and alcohol 
consumption) with the risk of type 2 diabetes. (Study I, III)  
 
 
The second aim of this study was to review the association between coffee drinking and glucose 
tolerance, the glucose and insulin levels. (Study II) 
 
 
The third aim of this study was to evaluate the relationship between coffee drinking and serum 
γ-glutamyltransferase on the risk of type 2 diabetes. (Study IV)  
 
 
The fourth aim of this study was to assess the association between coffee consumption and 
cardiovascular disease mortality among diabetic subjects. (Study V) 
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 4.      POPULATION AND METHODS 
4.1     Study population 
This study design is based on the FINRISK database. FINRISK is a large population survey on 
the risk factors of chronic, noncommunicable diseases. The survey is carried out every five years 
using independent, random and representative population samples of different parts of Finland. 
Data from the FINRISK surveys are used for many different research projects and for the national 
health monitoring needs. In addition to CVD and the classical risk factors, the recent research 
activities also deal e.g. with asthma and allergy, alcohol, socioeconomic factors and genetic 
epidemiology (Table 2). 
 
Table 2. Finrisk Study: Some parameters in the baseline survey among the entire population according to baseline examination years. 
 1972 1977 1982 1987 1992 1997 2002 Total 
No.of participants 11870 11408 9343 6235 6051 8259 8847 62013 
Sex (men %)* 49.0 48.6 49.4 47.7 47.1 50.0 46.4 48.4 
Sex (women %)* 51.0 51.4 50.6 52.3 52.9 50.0 53.6 51.6 
Age (years) 41.5 44.3 44.8 45.1 45.2 48.5 48.2 45.1 
Age range (years) 25-59 25-64 25-64 25-64 25-64 25-74 25-74 25-74 
Follow-up time (years)         
Education (years) 7.8 8.1 9.1 9.9 11.2 11.4 12.3 9.7 
Body mass index 25.9 26.1 26.1 26.5 26.3 26.7 26.9 26.3 
Waist circumference (cm) - - - 86 87 88 89 88 
Waist-to-hip-ratio - - - 0.84 0.85 0.86 0.90 0.87 
Systolic blood pressure (mmHg) 146 144 141 140 136 136 137 141 
Diastolic blood pressure (mmHg) 91 88 84 84 82 82 79 85 
Total cholesterol (nnol/L) 6.6 6.4 6.1 6.0 5.6 5.6 5.6 6.0 
HDL-cholesterol (mmol/L) - - 1.34 1.44 1.40 1.39 1.50 1.42 
Triglycerides (mmol/L) - - - - 1.53 1.50 1.44 1.49 
Serum gamma-glutamyltransferase (GGT) 
(U/L)  
- - 22.7 22.6 28.1 35.9 34.4 29.0 
C-Reactive protein CRP (mg/L) - - - - - 2.43 1.74 2.06 
Coffee consumption (cups/day) 5.4 5.0 5.2 5.1 4.4 4.3 4.2 4.9 
Tea consumption (cups/day) 0.6 0.8 1.0 0.7 0.9 0.9 0.8 0.8 
Milk consumption (cups/day) 4.0 3.6 2.9 2.5 2.1 2.1 2.1 2.9 
Current smokers (%)* 33.0 29.1 30.0 27.5 29.7 25.3 27.7 29.2 
Alcohol drinkers (%)* 46.6 45.0 44.8 47.8 60.8 56.7 65.4 51.6 
History of diabetes (%)* 1.3 2.5 2.0 2.5 2.0 3.3 3.3 2.4 
Occupational physical activity† + + + + + + + + 
Commuting physical activity† + + + + + + + + 
Leisure-time physical activity† + + + + + + + + 
Dietary habits(FFQ) - - - - + + +  
Values are given means unless otherwise indicated. 
*Values are percentages. 
† ”+” data are avaiable; ”-” data are not avaiable. 
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 Baseline surveys were carried out in two eastern Finnish provinces, North Karelia and Kuopio in 
1972 and 1977, and in the Turku-Loimaa region in southwestern Finland in 1982, 1987, 1992 and 
1997. The survey was expanded to the Helsinki capital area in 1992 and 1997 and the Oulu 
province in northern Finland in 1997 (Vartiainen et al., 2000). In each study year, according to 
the international WHO MONICA (MONItoring trends and determinants in CArdiovascular 
disease) project protocol (Pajak et al. 1988), the sample was randomly drawn from the population 
aged 25-64 and was stratified so that in each area at least 250 subjects were chosen from both 
sexes and each 10-year age group. In 1997, an additional sample of subjects aged 65-74 years 
was conducted.  
 
The surveys were independent, i.e., the study subjects were chosen from the population randomly 
for each survey. Participants who belonged to more than one survey were only included in the 
first survey (Table 2).  
 
Study ethical consideration The study was conducted according to the national data protection 
legislation, the ethical rules of the Finnish National Public Health Institute, and the rules and 
principles of the Helsinki Declaration. 
  
Study participants Study I was limited to surveys from 1982, 1987, and 1992 and included the 
participants between the ages 35 to 64. The final sample in study I comprised 6,974 men and 
7,655 women.  
 
In study II a sub-sample (age 45 to 64) comprising 3404 subjects (Tuomilehto et al. 1991) in 1987 
and of 2833 subjects in 1992 were invited to receive the standard OGTT at the baseline. Since the 
fasting time was short in 1987, all the subjects with an abnormal OGTT result at the first screening 
were invited to attend the second OGTT soon after. In addition, a control group, matched for the 
10-year age group and gender, with normal glucose tolerance in the first OGTT was also invited to 
the second OGTT in 1987. The second OGTT in 1987 was performed after an overnight fast. A 
total of 803 participants in 1987 and 2153 participants in 1992 attended the OGTT. 
  
Studies III and IV, also included, in addition to the surveys from 1982, 1987, and 1992, 
participants from the survey in 1997. In studies III and IV, the analyses were limited to 
participants between the ages 35 to 74. These two analyses included a total of 10,188 men and 
11,197 women for study III and 10,666 men and 11,160 women for study IV. 
 
Study V included participants from all six surveys from 1972 to 1997. Furthermore, participants’ 
age was expanded from 25 to 74 years. This evaluation included a total of 4,453 patients with a 
type 2 diabetes diagnosis. 
 
The exclusion criteria The exclusion criteria include subjects with known diabetes at the 
baseline (study I, II, III, and IV), diagnosed with CHD or stroke (study I, III, IV, and V), 
having type 1 diabetes at the baseline or detected during the follow-up period (study I-V), and 
subjects with missing data in all five studies.   
The analyses excluded participants younger than 25 (study V), 35 (study I, III, IV), and 45 
(study II), and older than 64 (study I, II) and 74 (study III, IV, V). 
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 Participation rate The participation rates were varied by the year and sex, but it was not less than 
74% and up to 88% in all five studies. 
 
4.2         Measurements 
4.2.1        Questionnaire 
Along with the invitation to the survey, a self-administered questionnaire was sent to the 
participants to be completed at home before arrival to the health care center for anthropometric 
measurements. Then it was checked by study nurses at the survey sites. The questionnaire 
included questions on medical history, socioeconomic factors, smoking habits, physical activity, 
dietary habits, and education level.   
 
Coffee & tea assessment For the assessment of  coffee and tea consumption, the participates 
were asked, “How many cups of coffee or tea do you drink per day (1 cup of coffee equal to 1 
deciliter; 1 cup of tea equal to 2 deciliter)?” (Greenland 1993) Coffee consumption was 
categorized into three to five categories (Study I: <2, 3-4, 5-6, 7-9, and 10 cups/day; Study III: 
0-2, 3-6, and 7 cups/day; Studies IV, V: 0-2, 3-4, 5-6, and 7 cups/day).  
The categorization differed between the studies, to ensure enough sample size in each category. 
Tea consumption was categorized into three categories in all studies, none, 1-2 cups, and 3 cups, 
because only a few people drank tea.  
The type of coffee consumption was assessed in the surveys of 1987 and 1992. More than 80% of 
the Finnish coffee consumers used filtered coffee at the baseline. 
 
Physical activity included occupational, commuting, and leisure time physical activity. The 
subjects reported their occupational physical activity according to the following three categories: 
low, moderate, and high. The daily commuting return journey to work was grouped into three 
categories: (i) using motorized transportation, or not working outside home (0 min of walking or 
cycling); (ii) walking or bicycling 1–29 min; (iii) walking or bicycling for more than 30 min. 
Self-reported leisure time physical activity was classified into three categories: low, moderate, 
and high; (i) low was defined as subjects who reported low levels of occupational, commuting 
(<30 min) and leisure time physical activity; (ii) moderate was defined as subjects who reported 
only one of the three kinds of moderate to high physical activity; (iii) high was defined as 
subjects who reported two or three kinds of moderate to high physical activity. 
 
Alcohol consumption was assessed with questions on type (beer, wine, liquor, spirit), frequency, 
and amount of alcohol consumed during the previous week. Based on this information, an alcohol 
index was calculated indicating the intake of absolute alcohol in grams per week.  
In study IV, since questions on alcohol consumption were different between the first two surveys 
(1972 and 1977) and the latter surveys, the participants were categorized into abstainers and 
alcohol users.  
 
Education level, measured as the total number of school years, was divided into birth cohort 
specific tertiles.  
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 Smoking Based on the responses, the participants were classified as never, ex-, and current-
smokers. Current smokers were categorized into those who smoked less than 20 or 20 or more 
cigarettes per day. 
 
Dietary assessment The participants’ diet and food choices were assessed by two type questions. 
First, the amount of food consumed daily and second, the frequency of consumption of 
vegetables and fruits over the last week (<1 time/week, 1-2 times/week, 3-5 times/week, 6-7 
times/week), and the frequency of consumption of sausages over the past 12 month (<1 
time/month, 1-2 times/month, 1 time/week, 2 times/week, almost daily, >1 time/day) were 
inquired. 
 
4.2.2. Anthropometric and laboratory measurements 
At the survey site, specially trained research nurses measured height and weight of the 
participants who were in light clothing, without shoes by using the standardized WHO MONICA 
protocol (Pajak et al. 1988). The body mass index (BMI, kg/m2) was used as a measure of 
relative body weight as a continuous variable. Blood pressure was measured from the right arm 
of the participant who was seated for 5 min before the measurement using a standard 
sphygmomanometer.  
After blood pressure measurement, a venous blood specimen was drawn. Total serum cholesterol 
was determined using the Lieberman-Burchard method in 1972 and 1977, and an enzymatic 
method (CHOD-PAP, Boehringer MANNHEIM, Mannheim, Germany) since 1982. The 
enzymatic assay method gave 2.4% lower values than the Lieberman-Burchard method. The 
cholesterol values from 1972 and 1977 were corrected by this percentage.  
 
In addition, a 2-hour 75g OGTT was carried out by trained nurses in the sub sample of the cohort 
in study II. Furthermore, serum GGT level was determined from fresh venous blood serum 
samples using a kinetic method (Oy Medix Biochemica AB, Kauniainen, Finland) based on the 
recommendation of European Committee for Clinical Laboratory Standards (study V).  
All samples were analyzed in the same central laboratory located at the Finnish National Public 
Health Institute in Helsinki.  
 
 
4.3        Diagnosis of Diabetes  
 
During the follow-up period, data on the occurrence of new type 2 diabetes cases were obtained 
from the National Hospital Discharge Register and the Social Insurance Institutions nationwide 
register of persons receiving drug reimbursement for diabetes medication. To receive the special 
reimbursement, the diagnosis of diabetes is assigned by the person’s own physician, usually a 
general practitioner, internist, or specialist in occupational medicine. The statements documenting 
the diagnosis are then reviewed according to current criteria by expert physicians of the Social 
Insurance Institution. Thus, the register data include the drug treated diabetic, but not those who 
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 are on diet only. Under the Finnish law, all persons with type 1 or type 2 diabetes are eligible for 
the reimbursement, and thus this registry probably includes virtually all new cases that need 
medication for type 2 diabetes. Nevertheless, it is well known that the majority of type 2 diabetic 
patients sooner or later will require pharmacotherapy, and thus, it is likely that the date of 
ascertainment of diabetes is delayed in our cohort. The National Hospital Discharge Register 
includes in-hospital admissions of patients to hospitals with a primary or secondary diagnosis of 
diabetes in Finland nationwide. 
 
4.3.1     Prospective follow-up 
 
In study I, the follow-up of each participant continued until the diagnosis of type 2 diabetes, the 
end of 1998, or until death. In study III, the follow-up of each cohort member continued until the 
date of the diagnosis of type 2 diabetes, death, or until the end of 2003. In study IV, follow-up 
time was calculated from the baseline examination to the date of diagnosis of type 2 diabetes, 
death or the end of 2002.  
In study V, study cohorts were followed until death or the end of 2003 through computerized 
register linkage. Mortality data were obtained from Statistics Finland and were linked with the 
survey data using the personal identification number assigned for every resident in Finland. The 
Eighth, Ninth and Tenth Revisions of the International Classification of Diseases were used to 
identify diabetic cases (250, 250.0 250.2, and E11) and deaths from CHD (410-414 and I20-I25), 
stroke (430-438 and I60-I66), and CVD (390-459 and I00-I99). 
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 4.4      Statistical analyses 
4.4.1     Prospective studies (study I, III, IV, V) 
 
 
Sex-specific differences in risk factors based on different levels of coffee consumption were tested 
using either the univariate analysis of variance (ANOVA) or logistic regression after adjustment for 
age and study year. The Cox proportional hazard models were used to estimate the single and joint 
effects of coffee consumption, and physical activity, BMI, and alcohol consumption on the risk of 
type 2 diabetes. Tests for trends were conducted using median values for each category of coffee 
consumption (studies I, III, IV). The proportional hazard assumption in the Cox models was assessed 
with graphical methods and with models including time-by-covariate interactions (Cox 1972) (studies 
I, III, V). In general, all proportionality assumptions were appropriate.  
The assumption of Cox proportional hazard model was tested using Schoenfeld residuals by the 
Stata statistical [package] (STATA press 2001) and found not to be violated (study IV). 
In study IV, analyses were stratified by the serum GGT levels classified into two classes using 
the 75th sex specific percentiles as the cut-points (40 U/L in men, 21 U/L in women). 
In study V, the associations between coffee consumption at the baseline and the risk of total, 
CVD, CHD, and stroke mortality were analyzed by using Cox proportional hazards models. 
Different levels of coffee consumption were included in the models as dummy variables and the 
significance of the trend over different categories of coffee consumption was tested in the same 
models by giving an ordinal numeric value for each dummy variable. 
 
4.4.2     Cross-Sectional study (study II) 
Linear regression models were applied to test the association between coffee consumption and 
glucose and insulin levels (study II). Logistic regression was applied to the association between 
coffee consumption and hyperglycaemia and hyperinsulinemia (study II). All analyses were 
adjusted for age, study year, BMI, systolic blood pressure, education, alcohol and tea drinking, 
smoking and occupational, commuting and leisure time physical activity.  
First level of interactions between coffee consumption and sex were analyzed to assess whether 
the effect differed between the sexes. Because no statistically significant interactions were found, 
men and women were combined in the analyses adjusted for sex. The possibility of a non-linear 
association between coffee consumption and glucose and insulin levels (hyperglycaemia and 
hyperinsulinemia) was tested by a likelihood ratio test comparing regression models without and 
with the squared term for the relevant coffee consumption variable. No significant quadratic or 
higher order effects on the association between coffee consumption and glucose and insulin 
levels were observed.  
 
All statistical analyses in studies I, II, III and V were performed with SPSS for Windows 11.0-13.0 
(2002-2005) (SPSS Inc, Chicago, Ill). In study IV analyses were carried out by the PHREG 
procedure of the SAS statistical package (version 8.02) (SAS institute 2003).  
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 5.        RESULTS 
5.1       Coffee consumption and the incidence of type 2 diabetes 
In studies I, II, and IV we analyzed the association between coffee consumption and risk of type 
2 diabetes. 
In study I (Table 3), during the 12 years of follow-up period time 381 individuals with type 2 
diabetes were found. Age- and study year-adjusted hazards ratios (HRs) of diabetes in people 
who drank 0-2, 3-4, 5-6, 7-9, and 10 cups of coffee were 1.00, 0.72, 0.49 0.47, and 0.26 
(P=0.002 for trend) in women, and 1.00, 0.83, 0.88, 0.86, and 0.69 (P=0.74 for trend) in men.  
After further adjustments for other covariates (BMI, systolic blood pressure, education, occupational, 
commuting and leisure time physical activity, alcohol and tea consumption, and smoking), this 
inverse association still remained significant among women (P<0.001 for trend). In men, a similar 
trend was observed and the risk of diabetes was significantly reduced in those who drunk at least 10 
cups of coffee (HRs, 0.45 95% CI, 0.25-0.81). When men and women were combined, sex- and 
multivariate-adjusted HRs by the coffee consumption of 0-2, 3-4, 5-6, 7-9, and 10 cups were 1.00, 
0.76, 0.54, 0.55, and 0.39 (P<0.001 for trend). The risk of diabetes did not differ between total coffee 
abstainers and light coffee drinkers (HRs, 1.20 95% CI, 0.74-1.97). Sex- and multivariate-adjusted 
(including coffee consumption) HRs of diabetes by the tea consumption of 0, 1-2, and 3 cups were 
1.00, 0.81, and 0.98 (P=0.27 for trend) (Table 4). 
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5.1.1     Joint association of coffee consumption and other factors on the risk of 
type 2 diabetes  
 
In study III (Table 5, 6), 964 cases of type 2 diabetes were identified during a mean follow-up 
period of 13.4 years. Multivariate-adjusted (age, study year, systolic blood pressure, education, 
smoking, physical activity, body mass index, and fruit, vegetable, sausage, bread, alcohol, and tea 
consumption) HRs of type 2 diabetes in participants who drank 0-2, 3-6 and >7 cups of coffee 
were 1.00, 0.77, and 0.66 in men, and 1.00, 0.71, and 0.52 in women. When both sexes were 
combined, sex- and multivariate-adjusted HRs were 1.00, 0.75, and 0.61 (Table 7).  
When coffee consumption was examined as a continuous variable, multivariate-adjusted HRs of 
type 2 diabetes associated with an increment of one cup of coffee per day were 0.97 in men, 0.91 
in women, and 0.95 in both sexes combined.  
In multivariate analyses we estimated the joint effects of coffee consumption and any one of the 
physical activity (Figure 4a), BMI (Figure 4b), and alcohol consumption (Figure 4c) on the risk 
of type 2 diabetes. Multivariate-adjusted HRs of type 2 diabetes decreased significantly with 
increasing physical activity. The HRs of type 2 diabetes associated with low, moderate, and high 
physical activity were 1.00, 0.62, and 0.50 in men, and 1.00, 0.80, and 0.65 (P=0.009 for the 
trend) in women. 
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 Table 5. Baseline characteristics of study sample by sex (study III). 
Variable Men Women P value for 
trend 
Number of participants 10188 11197  
Age (y) 50 50 0.80 
BMI (kg/m2) 27 27 <0.001 
Diastolic blood pressure (mmHg) 87 83 <0.001 
Systolic blood pressure (mmHg) 142 139 <0.001 
Education level (y) 10 10 <0.001 
Bread consumption (slices/day) 6 5 <0.001 
Coffee consumption (%)   
  0-2 cups/day 19 20 
  3-6 cups/day 56 65 
  ≥7 cups/day 24 14 
<0.001 
Physical activity (%)   
  Low 11 13 
  Moderate 43 41 
  High 46 46 
<0.001 
BMI (%)   
  <25 kg/m2 31 42 
  25-29.9 kg/m2 50 37 
  30 kg/m2 19 21 
<0.001 
Smoking (%)   
  Never 36 73 
  Past 29 10 
  Current 35 17 
<0.001 
Tea consumption (%)   
  None 64 61 
  1-2 cups/day 25 31 
  3 cups/day 10 8 
<0.001 
Alcohol consumption (%)   
  None 38 60 
  1-100 g/week 38 35 
  >100 g/week 25 5 
<0.001 
Daily consumption of vegetables (%) 17 30 <0.001 
Daily consumption of fruits (%) 21 40 <0.001 
Almost daily consumption of sausage (%) 17 23 <0.001 
Values are as means or percentages. 
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 Table 6. Baseline characteristics according to different levels of coffee consumption by sex (study III). 
Coffee consumption 
(men) 
Coffee consumption  
 (women) 
 
0-2 
cups/day 
3-6  
cups/ day 
≥7  
cups/day 
 
P value 
for 
trend 
0-2  
cups/day 
3-6  
cups/day 
≥7  
cups/day 
 
P value for 
trend 
Number of participants 1986 5704 2498  2257 7314 1626  
Age (y) 51 50 48 <0.001 51 50 47 <0.001 
BMI (kg/m2) 27 27 27 0.08 26 27 27 0.22 
Diastolic blood 
pressure (mmHg) 
88 87 86 <0.001 83 83 81 <0.001 
Systolic blood pressure 
(mmHg) 
143 143 141 <0.001 139 139 135 <0.001 
Education level (y) 10 10 9 <0.001 11 10 10 <0.001 
Bread consumption 
(slices/day) 
6 6.0 7.0 <0.001 4.5 4.8 5 <0.001 
Physical activity (%)       
  Low 11 11 10 16 12 14 
  Moderate 47 43 41 43 40 37 
  High 42 46 49 
<0.001 
41 47 49 
<0.001 
BMI (%)       
  <25 kg/m2 33 30 31 44 42 41 
  25-29.9 kg/m2 49 51 49 35 37 37 
  30 kg/m2 18 19 19 
0.22 
20 21 22 
0.27 
Smoking (%)       
  Never 50 37 24 78 74 58 
  Past  30 32 24 12 10 11 
  Current 20 32 53 
<0.001 
10 16 31 
<0.001 
Tea consumption (%)       
  None 32 66 87 34 65 84 
  1-2 cups/day 39 27 10 44 30 14 
  3 cups/day 28 7 3 
<0.001 
22 4 1 
<0.001 
Alcohol consumption 
(%) 
      
  None 36 36 42 57 60 63 
  1-100 g/week 38 39 35 37 36 32 
  >100 g/week 26 25 23 
<0.001 
5 4 4 
0.002 
Daily consumption of 
vegetables (%) 
22 18 12 <0.001 35 29 23 <0.001 
Daily consumption of 
fruits (%) 
26 21 16 <0.001 42 41 34 <0.001 
Almost daily 
consumption of 
sausage (%) 
17 16 19 0.017 21 23 22 0.10 
Values are as means or percentages. 
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Figure 4a.
 
Figure 4b 
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Figure 4. Hazard ratios of type 2 diabetes with joint effects of coffee consumption and physical activity (a), coffee 
consumption and BMI (b), coffee and alcohol consumption (c). Cox proportional hazards model adjusted for age, 
study year, sex, education, systolic blood pressure, bread consumption, frequency of vegetable consumption, 
frequency of fruit consumption, frequency of sausage consumption, tea consumption, and smoking (also for BMI and 
alcohol consumption in a, physical activity and alcohol consumption in b, physical activity and BMI in c). *P <0.05 
compared with referent group. 
 
 
 
 
 
Multivariate-adjusted HRs of type 2 diabetes at different levels of BMI were 1.00, 2.90, and 8.46 
in men, and 1.00, 2.78, and 9.59 in women.  
Multivariate-adjusted HRs of type 2 diabetes in participants who drank 0, 1-100, and >100 g of 
alcohol per week were 1.00, 0.91, and 0.74 in men, and 1.00, 0.74, and 0.23 in women. When 
 both sexes were combined, the same results were observed. No significant association between 
tea consumption and the risk of type 2 diabetes was found (Table 7). 
 
An inverse association between coffee consumption and the risk of type 2 diabetes was found in 
subjects at different levels of physical activity, at different levels of BMI, and in alcohol drinkers 
and non-drinkers.The joint association of coffee consumption, physical activity, and BMI with 
the risk of type 2 diabetes is shown in Figure 5. After adjustment for all confounding factors, 
coffee consumption was inversely associated with type 2 diabetes incidences at any level of 
physical activity and BMI; the direct association of BMI and the observed effect of physical 
activity on the risk of type 2 diabetes was also found at different levels of coffee consumption. 
The risk of development of type 2 diabetes was about 11 times higher in obese subjects reporting 
low levels of physical activity and drinking less than two cups of coffee compared to non-obese 
persons reporting moderate or high level of physical activity and drinking at least seven cups of 
coffee daily. Among the obese and inactive people, coffee drinking (7 versus 0-2 cups per day) 
reduced the risk of type 2 diabetes to approximately half.  
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Figure 5. Hazard ratios of type 2 diabetes with joint effects of coffee consumption, physical activity, and BMI. Cox proportional hazards model 
adjusted for age, study year, sex, education, systolic blood pressure, bread consumption, frequency of vegetable consumption, frequency of fruit 
consumption, frequency of sausage consumption, tea and alcohol consumption, and smoking. Inactivity was defined as low physical activity; 
activity was defined as moderate or high physical activity.  
*P <0.05 compared with referent group. 
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 5.1.2     Coffee, serum GGT level and type 2 diabetes 
 
In study IV (Table 8) the same significant inverse association occurred between the coffee 
consumption and risk of type 2 diabetes among both men and women. Additional adjustment for 
GGT as a potential confounder did not change the association. Sex- and multivariate-adjusted (age, 
BMI, alcohol consumption, smoking, and physical activity) HRs of incident type 2 diabetes by 
coffee consumption decreased linearly with increasing amounts of coffee, being 0.64 for people 
drinking seven cups or more per day compared to those drinking 0-2 cups of coffee (Table 9). 
 
Table 8. Baseline characteristics of participants by volume of coffee consumption (study IV). 
Daily coffee consumption, cups  
0-2 3-4 5-6 7 
Men     
No. of subjects, (%) 1994 (19) 2811 (26) 3275 (31) 2586 (24) 
Age, mean (SD), y 52 52 50 48 
GGT (U/L, mean) 46 39 33 31 
Body mass index, mean (SD) 27 27 27 27 
Alcohol consumption, No, (%)      
  0 g  18 24 31 27 
  1-69 g 19 28 32 21 
70-139 g 18 27 30 25 
140-209 g  19 28 31 21 
> 210 g 24 29 24 23 
Physical activity at least twice per week (%) 21 28 30 21 
Current smoking, No. (%) 14 20 29 47 
Women     
No. of subjects, (%) 2205 (20) 3849 (34) 3481 (31) 1625 (15) 
Age, mean (SD), y 51 51 50 47 
GGT (U/L, mean) 26 20 18 17 
Body mass index, mean (SD) 26 27 27 27 
Alcohol consumption, No, (%)     
0 g 19 33 32 15 
1-34 g 21 36 28 15 
35-69 g 20 36 28 15 
> 70 g 12 10 9 9 
Physical activity at least twice per week (%) 48 50 45 40 
Current smoking, No. (%) 10 25 35 30 
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 Table 9. Coffee consumption and incident diabetes (study IV). 
Coffee intake (frequency/day) 
 
0-2 3-4 5-6 7 
P value for 
trend 
Men      
No of cases/pop. 87/1994 117/2811 164/3274 115/2586  
Person-years 22105 32919 40353 33190  
Incidence rate/1000  
Person-years 
3.94 3.55 4.06 3.46  
Age-adjusted RR 1.00 
0.89 
(0.67-1.17) 
1.01 
(0.78-1.13) 
0.91 
(0.69-1.21) 
0.86 
Multivariate* RR 1.00 
0.89 
(0.68-1.18) 
0.87 
(0.67-1.13) 
0.71 
(0.53-0.94) 
0.02 
Multivariate** RR 
1.00 
 
0.93 
(0.7-1.22) 
0.91 
(0.69-1.18) 
0.74 
(0.55-0.99) 
0.05 
Women      
No of cases/pop. 83/2206 131/3849 122/3481 43/1625  
Person-years 25860 48028 47612 23022  
Incidence rate/1000  
Person-years 
3.21 2.73 2.56 1.87  
Age-adjusted RR 1.00 
0.80 
(0.61-1.05) 
0.76 
(0.57-1.0) 
0.64 
(0.44-0.92) 
0.02 
Multivariate* RR 1.00 
0.75 
(0.57-0.98) 
0.63 
(0.47-0.83) 
0.47 
(0.33-0.69) 
<0.0001 
Multivariate** RR 1.00 
0.78 
(0.59-1.03) 
0.66 
(0.49-0.87) 
0.50 
(0.34-0.72) 
<0.0001 
Men and women***      
No of cases/pop. 170/4200 248/6660 286/6756 158/4211  
Person-years 47966 80947 87965 56212  
Incidence rate/1000  
Person-years 
3.54 3.06 3.25 2.81  
Age-adjusted RR 1.00 
0.85 
(0.70-1.04) 
0.89 
(0.73-1.07) 
0.80 
(0.64-0.99) 
0.10 
Multivariate* RR 1.00 
0.83 
(0.68-1.0) 
0.75 
(0.62-0.91) 
0.61 
(0.49-0.76) 
<0.0001 
Multivariate** RR 1.00 
0.85 
(0.70-1.04) 
0.78 
(0.65-0.95) 
0.64 
(0.51-0.80) 
<0.0001 
* Adjusted for age, BMI, alcohol consumption, smoking, and physical activity 
** Additional adjustment for GGT 
***All analyses additionally adjusted for sex 
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 The association between coffee consumption and incident type 2 diabetes was stratified by the 
baseline GGT level (<75th, 75th percentiles). No association existed between coffee 
consumption and the incidence of type 2 diabetes among men with low GGT levels, but at a high 
GGT level an inverse tendency appeared, however, P-value for the trend failed to reach the level 
of significance. Among women with a low GGT level a non-significant inverse trend between 
coffee consumption and incident diabetes was detected. At a high GGT level a strong inverse 
association occurred and multivariate-adjusted HRs of diabetes in women who drank 0-2, 3-4, 5-6, 
and 7 cups of coffee were 1.00, 0.75, 0.59, and 0.44. When data for men and women were 
combined, in the highest quartile of the GGT level sex-, and multivariate-adjusted HRs for type 2 
diabetes were 1.00, 0.77, 0.70, 0.65, but no association between coffee and risk for type 2 
diabetes was found in pooled data at lower levels of GGT (<75th percentile). The interaction 
between coffee, GGT, and sex on the risk of type 2 diabetes has been measured. A significant 
interaction effect of GGT and coffee consumption on the risk of type 2 diabetes appeared in the 
data of women (P=0.05 for interaction) and in both sexes combined (P=0.02 for interaction) 
(Table 10). 
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Table 10. Coffee consumption and incident diabetes stratified by baseline GGT level (study IV). 
Coffee intake (frequency/day)  
0-2 3-4 5-6 >=7 
P value for 
trend 
Men (P of interaction=0.18 )  
GGT<75th percentile (40U/L)      
No of cases 38/1335 64/2032 110/2519 73/2049  
Person-years 16019 24992 32838 27181  
Incidence rate/1000 
Person-years 2.37 2.56 3.35 2.68  
Age-adjusted RR 1.00 1.06 (0.71-1.58) 
1.36 
(0.94-1.97) 
1.18 
(0.80-1.75) 
0.22 
 
Multivariate* RR 1.00 1.06 (0.71-1.59) 
1.14 
(0.79-1.66) 
0.94 
(0.63-1.40) 0.75 
GGT>=75th percentile (40U/L)      
No of cases 49/659 53/779 54/756 42/537  
Person-years 6087 7927 7515 6009  
Incidence rate/1000 
Person-years 8.05 6.69 7.18 6.99  
Age-adjusted RR 1.00 0.82 (0.56-1.21) 
0.93 
(0.63-1.37) 
0.92 
(0.61-1.41) 0.89 
Multivariate* RR 1.00 0.85 (0.58-1.26) 
0.81 
(0.55-1.20) 
0.68 
(0.44-1.05) 0.08 
Women (P of interaction=0.05 )  
GGT<75th percentile (21U/L)      
No of cases 33/1452 59/2710 76/2710 30/1322  
Person-years 18390 36692 39428 19615  
Incidence rate/1000 
Person-years 1.79 1.61 1.93 1.53  
Age-adjusted RR 1.00 0.82 (0.53-1.25) 
0.95 
(0.63-1.43) 
0.85 
(0.52-1.40) 0.85 
Multivariate* RR 1.00 0.84 (0.55-1.30) 
0.86 
(0.57-1.30) 
0.68 
(0.41-1.13) 0.20 
GGT>=75th percentile (21U/L)      
No of cases 50/754 72/1139 46/771 13/303  
Person-years 7471 11336 8184 3407  
Incidence rate/1000 
Person-years 6.69 6.35 5.62 3.82  
Age-adjusted RR 1.00 0.92 (0.64-1.31) 
0.85 
(0.57-1.27) 
0.67 
(0.36-1.24) 0.19 
Multivariate* RR 1.00 0.75 (0.52-1.09) 
0.59 
(0.39-0.88) 
0.44 
(0.24-0.82) 0.002 
Men and women** (P of interaction=0.02 )  
GGT<75th percentile      
No of cases 71/2787 123/4742 186/5229 103/3371  
Person-years 34409 61684 72266 46796  
Incidence rate/1000 
Person-years 2.06 1.99 2.57 2.20  
Age-adjusted RR 1.00 0.95 (0.71-1.27) 
1.17 
(0.89-1.54) 
1.04 
(0.77-1.41) 0.38 
Multivariate* RR 1.00 0.96 (0.71-1.28) 
1.01 
(0.76-1.33) 
0.82 
(0.60-1.12) 0.95 
GGT>=75th percentile      
No of cases 99/1413 125/1918 100/1527 55/840  
Person-years 13557 19263 15699 9417  
Incidence rate/1000 
Person-years 7.30 6.49 6.37 5.84  
Age-adjusted RR 1.00 0.88 (0.68-1.14) 
0.89 
(0.68-1.18) 
0.85 
(0.61-1.19 0.51 
46
Multivariate* RR 1.00  
0.77 
(0.59-1.01) 
0.70 
(0.53-0.93) 
0.65 
(0.46-0.91) 0.001 
* Adjusted for age, BMI, alcohol consumption, smoking, and physical activity 
**All analyses additionally adjusted for sex 
 5.1.3     Coffee consumption and risk of type 2 diabetes in subgroup analyses 
 
Multivariate-adjusted inverse association between coffee consumption and diabetes risk was 
present in subjects aged 35-49 (P=0.23 for trend) and 50-64 years (P=0.001 for trend). Similarly, 
the inverse association was observed in non-smokers (P=0.001 for trend), in non-alcohol drinkers 
(P<0.001 for trend) and in overweight participants (P=0.01 for trend). A nonsignificant 
association was observed in smokers (P=0.07 for trend), in healthy weight participants (P=0.35 
for trend), in participants who were obese (P=0.05 for trend), in alcohol drinkers (P=0.25 for 
trend), in filtered coffee drinkers (P=0.07 for trend), and in pot-boiled coffee drinkers (P=0.06 for 
trend). (study I) (Table 11). 
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 5.1.4     Type of the coffee and risk of type 2 diabetes 
 
The type of coffee consumed by the participants was assessed in the surveys of 1987 and 1992. 
More than 80% of the Finnish coffee consumers used filtered coffee at the baseline. The 
likelihood ratio test was applied to determine the interaction between the type of coffee and the 
amount of coffee on the risk of type 2 diabetes. No interaction occurred between the type of 
coffee and the amount of coffee for the risk of type 2 diabetes (P>0.1 for trend). Men and women 
who drank pot-boiled coffee, without filtering, showed a similar inverse trend in the risk of type 2 
diabetes in comparison with people who drank filtered coffee. After multivariate adjustment 
including the amount of coffee consumed, however, men who mainly drank pot-boiled coffee 
showed a 2.9 times higher risk for the development of diabetes compared with men who drank 
filtered coffee. This association was also observed among men and women combined (Table 12). 
 
 
Table 12. Hazard ratios for the development of type 2 diabetes by different type of coffee consumption according to the sex and  
age* (study I). 
No. of new cases Person-years Risk ratio  
Filtered 
coffee 
Pot cooked coffee 
without filter 
Filtered 
coffee 
Pot cooked coffee 
without filter 
Filtered 
coffee 
Pot cooked coffee 
without filter 
Men 40 36 25410 6915 1.00 2.86 (1.76-4.63) 
 Age <50 years  17 11 16001 2923 1.00 3.89 (1.65-9.21) 
 Age 50 years  23 25 9409 3992 1.00 2.72 (1.49-4.96) 
Women 38 26 29462 7943 1.00 1.30 (0.76-2.24) 
 Age <50 years  6 4 18032 3067 1.00 2.11 (0.45-9.99) 
 Age 50 years  32 22 11430 4876 1.00 1.29 (0.72-2.33) 
Men and women 
combined† 
78 62 54871 14858 1.00 2.04 (1.43-2.92) 
 Age <50 years  23 15 34034 5990 1.00 2.71 (1.33-5.53) 
 Age 50 years  55 47 20837 8868 1.00 1.87 (1.24-2.82) 
*Adjusted for age, study year, body mass index, systolic blood pressure, education, occupational physical activity (light, moderate, 
and active), walking or cycling to/from work (0, 1-29, and 30 minutes per day), leisure time physical activity (low, moderate, and 
high), cigarette smoking (never, past, and current smoking of 1-19 or 20 cigarettes per day), alcohol consumption (0, 1-100, 101-
300, and >300 g per week), tea consumption (none, 1-2, and 3 cups per day), and coffee consumption (0-2, 3-4, 5-6,  
7-9, 10 cups per day). This analysis only includes Finnrisk study years of 1987 and 1992. 
†Also adjusted for sex. 
 
5.2      Coffee consumption and glycemic markers  
Analyses in the study II (Table 13) revealed that coffee consumption was significantly and 
inversely associated with fasting insulin among men and with 2-hour glucose levels among 
women in age- and study year-adjusted analysis.  
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 After adjustment for all potential confounding factors (age, study year, BMI, systolic blood 
pressure, education, occupational, commuting, and leisure time physical activity, alcohol and tea 
drinking, and smoking), coffee consumption was significantly and inversely associated with 
fasting glucose, 2-hour plasma glucose, and fasting insulin among both men and women. For 
men and women together, we found that an increment of one cup of coffee per day was 
associated with 0.29 mg/ml lower fasting glucose, 1.16 mg/ml lower 2-hour glucose, and 0.24 
μU/ml lower fasting insulin (Table 14). 
 
 
Table 14. Linear regression analysis of the association between coffee consumption and glucose and insulin levels (study II) 
Regression coefficient (95% CI)  
Coffee consumption, cups/day Fasting glucose 2-hour glucose Fasting insulin 
Men     
 Adjustment for age and study year -0.18 (-0.39 to 0.03) -0.55 (-1.14 to 0.04) -0.14 (-0.24 to -0.03)‡ 
 Multivariate adjustment* -0.33 (-0.56 to -0.10)‡ -0.64 (-1.28 to -0.01)‡ -0.22 (-0.33 to -0.12)‡ 
Women     
 Adjustment for age and study year -0.10 (-0.35 to 0.15) -1.34 (-1.99 to -0.68)‡ -0.10 (-0.23 to 0.03) 
 Multivariate adjustment* -0.26(-0.50 to -0.01)‡ -1.77 (-2.43 to –1.12)‡ -0.26 (-0.38 to -0.14)‡ 
Men and women combined†    
 Adjustment for age and study year -0.15 (-0.31 to 0.01) -0.89 (-1.33 to -0.45)‡ -0.12 (-0.21 to -0.04)‡ 
 Multivariate adjustment* -0.29 (-0.45 to -0.12)‡ -1.16 (-1.61 to -0.70)‡ -0.24 (-0.31 to -0.16)‡ 
*Adjusted for age, study year, body mass index, systolic blood pressure, education, occupational and leisure time physical  
activity, walking or cycling to/from work, cigarette smoking, alcohol and tea consumption. 
†Adjusted also for sex. 
‡P value <0.05. 
 
After the adjustment for all confounding factors, coffee consumption was significantly and 
inversely associated with impaired fasting glucose, impaired glucose regulation, and 
hyperinsulinemia among both men and women. A significant inverse association also occurred 
between coffee consumption and isolated impaired glucose tolerance among women. Coffee 
consumption as a continuous variable showed that an increment of one cup of coffee per day was 
associated with a 10% lower risk of impaired fasting glucose, an 8% lower risk of isolated 
impaired glucose tolerance, a 9% lower risk of impaired glucose regulation, and an 11% lower 
risk of hyperinsulinemia if both men and women were combined (Table 15). 
 
 
 
 
 
 
 
 
 
 
 
51
 Ta
bl
e 
15
. A
dj
us
te
d 
od
d 
ra
tio
 o
f t
he
 a
ss
oc
ia
tio
n 
be
tw
ee
n 
co
ffe
e 
co
ns
um
pt
io
n 
an
d 
hy
pe
rg
ly
ca
em
ia
 a
nd
 h
yp
er
in
su
lin
em
ia
 (s
tu
dy
 II
) 
O
dd
 r
at
io
s (
95
%
 C
I)
 
  C
of
fe
e 
co
ns
um
pt
io
n,
 c
up
s/
d 
Im
pa
ir
ed
 fa
st
in
g 
gl
uc
os
e*
 
Is
ol
at
ed
 im
pa
ir
ed
 g
lu
co
se
 to
le
ra
nc
e*
 
Im
pa
ir
ed
 g
lu
co
se
 r
eg
ul
at
io
n*
 
H
yp
er
in
su
lin
em
ia
 
M
en
  
N
=9
78
 
N
=8
84
 
N
=1
05
1 
N
=1
05
1 
 A
dj
us
tm
en
t f
or
 a
ge
 a
nd
 st
ud
y 
ye
ar
 
0.
94
 (0
.8
8-
1.
00
) 
0.
97
 (0
.8
9-
1.
06
) 
0.
95
 (0
.9
0-
1.
01
) 
0.
96
 (0
.9
1-
1.
01
) 
 M
ul
tiv
ar
ia
te
 a
dj
us
tm
en
t†
 
0.
90
 (0
.8
3-
0.
98
) 
0.
97
 (0
.8
7-
1.
06
) 
0.
92
 (0
.8
7-
0.
99
) 
0.
89
 (0
.8
3-
0.
95
) 
W
om
en
  
N
=1
27
7 
N
=1
28
6 
N
=1
38
3 
N
=1
38
3 
 A
dj
us
tm
en
t f
or
 a
ge
 a
nd
 st
ud
y 
ye
ar
 
0.
94
 (0
.8
5-
1.
04
) 
0.
91
 (0
.8
3-
1.
01
) 
0.
92
 (0
.8
6-
0.
99
) 
0.
97
 (0
.9
2-
1.
03
) 
 M
ul
tiv
ar
ia
te
 a
dj
us
tm
en
t†
 
0.
88
 (0
.7
9-
0.
98
) 
0.
89
 (0
.8
0-
0.
99
) 
0.
89
 (0
.8
2-
0.
96
) 
0.
88
 (0
.8
2-
0.
94
) 
M
en
 a
nd
 w
om
en
 c
om
bi
ne
d‡
 
N
=2
25
5 
N
=2
17
0 
N
=2
43
4 
N
=2
43
4 
 A
dj
us
tm
en
t f
or
 a
ge
 a
nd
 st
ud
y 
ye
ar
 
0.
94
 (0
.8
9-
0.
99
) 
0.
94
 (0
.8
9-
1.
01
) 
0.
94
 (0
.9
0-
0.
98
) 
0.
96
 (0
.9
3-
1.
00
) 
 M
ul
tiv
ar
ia
te
 a
dj
us
tm
en
t†
 
0.
90
 (0
.8
5-
0.
96
) 
0.
92
 (0
.8
6-
0.
99
) 
0.
91
 (0
.8
7-
0.
96
) 
0.
89
 (0
.8
5-
0.
93
) 
*U
si
ng
 n
or
m
al
 g
lu
co
se
 to
le
ra
nc
e,
 fa
st
in
g 
gl
uc
os
e 
<1
10
 m
g/
dl
 a
nd
 2
-h
ou
r g
lu
co
se
 <
14
0 
m
g/
dl
 a
s r
ef
er
en
ce
 g
ro
up
 in
 th
e 
an
al
ys
is
 o
f h
yp
er
gl
yc
ae
m
ia
; i
m
pa
ire
d 
fa
st
in
g 
gl
uc
os
e,
 fa
st
in
g 
 
gl
uc
os
e 
11
0-
12
5 
m
g/
dl
; i
so
la
te
d 
im
pa
ire
d 
gl
uc
os
e 
to
le
ra
nc
e,
 2
-h
ou
r g
lu
co
se
 1
40
-1
99
 m
g/
dl
 a
nd
 fa
st
in
g 
gl
uc
os
e 
<1
10
 m
g/
dl
; i
m
pa
ire
d 
gl
uc
os
e 
re
gu
la
tio
n,
 fa
st
in
g 
gl
uc
os
e 
11
0-
12
5 
m
g/
dl
  
an
d/
or
 2
-h
ou
r g
lu
co
se
 1
40
-1
99
 m
g/
dl
; h
yp
er
in
su
lin
em
ia
; s
ex
- a
nd
 st
ud
y 
ye
ar
-s
pe
ci
fic
 q
ua
rti
le
 4
 o
f f
as
tin
g 
in
su
lin
.  
†A
dj
us
te
d 
fo
r a
ge
, s
tu
dy
 y
ea
r, 
bo
dy
 m
as
s i
nd
ex
, s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e,
 e
du
ca
tio
n,
 o
cc
up
at
io
na
l a
nd
 le
is
ur
e 
tim
e 
ph
ys
ic
al
 a
ct
iv
ity
, w
al
ki
ng
 o
r c
yc
lin
g 
to
/fr
om
 w
or
k,
 c
ig
ar
et
te
 sm
ok
in
g,
  
al
co
ho
l a
nd
 te
a 
co
ns
um
pt
io
n.
  
‡A
dj
us
te
d 
al
so
 fo
r s
ex
.
52
 5.3      Coffee, diabetes & cardiovascular mortality 
 
In the study V (Table 16), during the average follow-up of 20.8 years, 1,471 deaths were 
recorded, of which 909 were encoded as CVD, 598 as CHD, and 210 as the stroke. 
 
Table 16. Baseline characteristics of participants with type 2 diabetes by volume of coffee consumption* (study V) 
Daily coffee consumption, cups 
 
0-2 3-4 5-6 7 
P value 
for trend 
Number of participants 644 1041 1356 796  
Women, % 47.2 58.6 54.6 38.3  
Age, years 48.8±11.3 49.7±10.3 49.4±10.3 47.8±9.9 <0.001 
Body mass index, kg/m2 29.4±5.1 29.8±5.1 30.0±5.2 29.9±5.2 0.07 
Systolic blood pressure, mmHg 152±23 153±24 153±24 153±24 >0.2 
Diastolic blood pressure, 
mmHg 
93±13 93±13 93±13 92±13 >0.2 
Total cholesterol, mmol/l 6.3±1.3 6.5±1.3 6.6±1.4 6.6±1.3 0.001 
Education, years 8.3±3.9 8.0±3.6 7.5±3.2 7.2±3.1 <0.001 
Low physical activity, % 22.7 18.4 15.6 13.1 <0.001 
Alcohol drinkers, % 43.0 38.1 38.4 44.0 0.2 
Tea drinkers, % 58.1 39.9 21.3 11.4 <0.001 
Current smoking, % 22.8 20.7 25.5 45.9 <0.001 
*Values represent means±SD or percentages unless otherwise indicated. Adjusted for age, sex, and study year. 
 
 
 
Age-, sex-, and study year-adjusted HRs in participants who drank 0-2, 3-4, 5-6, and 7 cups of 
coffee daily were 1.00, 0.79, 0.72, and 0.79 for total mortality, 1.00, 0.81, 0.75, and 0.79 for 
CVD mortality, 1.00, 0.81, 0.77, and 0.71 for CHD mortality, and 1.00, 0.75, 0.62, and 0.90 for 
stroke mortality. After further adjustment for other co-factors (BMI, systolic blood pressure, total 
cholesterol, education, physical activity, alcohol and tea consumption, and smoking), these 
inverse associations became stronger and significant for total mortality, CVD mortality, and CHD 
mortality, but became no longer significant for stroke mortality (Table 17).  
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 Table 17. Hazard ratios of total, CVD, CHD, and stroke mortality by volume of coffee consumption among participants with 
 type 2 diabetes (study V) 
Daily coffee consumption, cups  
0-2 3-4 5-6 7 
P value for 
trend 
Total mortality       
   Number of deaths 247 384 529 311  
   Person-years 11,772 20,551 29,927 17,406  
   Hazard ratios, model 1a 1.00 0.79 (0.67-0.93) 0.72 (0.62-0.85) 0.79 (0.67-0.94) 0.001 
   Hazard ratios, model 1b 1.00 0.78 (0.66-0.92) 0.69 (0.59-0.82) 0.72 (0.60-0.87) <0.001 
   Hazard ratios, model 1c 1.00 0.77 (0.65-0.91) 0.68 (0.58-0.80) 0.70 (0.59-0.85) <0.001 
CVD mortality       
   Number of deaths  146 241 337 185  
   Hazard ratios, model 1a 1.00 0.81 (0.66-0.99) 0.75 (0.62-0.92) 0.79 (0.63-0.98) 0.04 
   Hazard ratios, model 1b 1.00 0.80 (0.65-0.99) 0.73 (0.59-0.90) 0.74 (0.58-0.94) 0.02 
   Hazard ratios, model 1c 1.00 0.79 (0.64-0.97) 0.70 (0.57-0.86) 0.71 (0.56-0.90) 0.006 
CHD mortality       
   Number of deaths  96 160 231 111  
   Hazard ratios, model 1a 1.00 0.81 (0.63-1.05) 0.77 (0.61-0.98) 0.71 (0.54-0.94) 0.09 
   Hazard ratios, model 1b 1.00 0.79 (0.61-1.03) 0.73 (0.57-0.95) 0.65 (0.48-0.88) 0.04 
   Hazard ratios, model 1c 1.00 0.78 (0.60-1.01) 0.70 (0.54-0.90) 0.63 (0.47-0.84) 0.01 
Stroke mortality       
   Number of deaths 35 54 69 52  
   Hazard ratios, model 1a 1.00 0.75 (0.49-1.14) 0.62 (0.41-0.94) 0.90 (0.59-1.40) 0.08 
   Hazard ratios, model 1b 1.00 0.79 (0.51-1.22) 0.66 (0.43-1.03) 0.94 (0.58-1.52) 0.15 
   Hazard ratios, model 1c 1.00 0.77 (0.50-1.19) 0.64 (0.41-0.99) 0.90 (0.56-1.45) 0.12 
aAdjusted for age, sex, and study year. 
bAdjusted for age, sex, study year, education, alcohol and tea consumption, and smoking status. 
cAdjusted for age, sex, study year, body mass index, systolic blood pressure, total cholesterol, education, alcohol and tea  
consumption, and smoking status. 
 
When coffee consumption was examined as a continuous variable, the multivariate-adjusted HRs 
associated with an increment of one cup of coffee per day were 0.96 for total mortality, 0.97 for 
CVD mortality, 0.96 for CHD mortality, and 0.99 for stroke mortality. The multivariate-adjusted 
HRs in people drinking 3 cups of coffee or more were 0.72 for total mortality, 0.73 for CVD 
mortality, 0.71 for CHD mortality, and 0.73 for stroke mortality compared to people drinking 0-2 
cups of coffee daily (Table 18).  
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 Table 18. Hazard ratios (95% CIs) of total, CVD, CHD, and stroke mortality by volume of coffee as continuous variable  
and by different volume of coffee (3 cups versus 0-2 cups) among participants with type 2 diabetes* (study V) 
Coffee as continuous variable 3 cups versus 0-2 cups of coffee daily  
Hazard ratios (95% CIs) P value for 
trend 
Hazard ratios (95% 
CIs) 
P value for 
trend 
Total mortality 0.96 (0.94-0.99) 0.002 0.72 (0.62-0.83) <0.001 
Cardiovascular mortality 0.97 (0.94-0.99) 0.02 0.73 (0.61-0.89) 0.001 
Coronary heart disease mortality 0.96 (0.93-0.99) 0.02 0.71 (0.57-0.90) 0.005 
Stroke mortality 0.99 (0.92-1.05) >0.2 0.73 (0.92-1.05) 0.12 
*Adjusted for age, sex, study year, body mass index, systolic blood pressure, total cholesterol, education, alcohol and tea  
consumption, and smoking status. 
 
 
A non-significant inverse association was found between tea consumption and mortality for total, 
CVD, and CHD, but not stroke mortality (Table 19). 
 
Table 19. Hazard ratios (95% CIs) of total, CVD, CHD, and stroke mortality by volume of tea 
 consumption among participants with type 2 diabetes  
Daily tea consumption, cups  
0 1-2 3 
P value for 
trend 
Total mortality      
   Number of deaths 1056 296 119  
   Person-years 55,944 17,436 6276  
   Hazard ratios, model 1a 1.00 0.88 (0.77-1.00) 0.92 (0.76-1.11) 0.13 
   Hazard ratios, model 1b 1.00 0.84 (0.74-0.97) 0.85 (0.70-1.04) 0.03 
   Hazard ratios, model 1c 1.00 0.84 (0.73-0.96) 0.87 (0.71-1.06) 0.03 
CVD mortality      
   Number of deaths  652 186 71  
   Hazard ratios, model 1a 1.00 0.89 (0.76-1.05) 0.88 (0.69-1.12) >0.2 
   Hazard ratios, model 1b 1.00 0.86 (0.72-1.02) 0.82 (0.63-1.06) 0.10 
   Hazard ratios, model 1c 1.00 0.85 (0.71-1.00) 0.85 (0.66-1.10) 0.11 
CHD mortality      
   Number of deaths  430 126 42  
   Hazard ratios, model 1a 1.00 0.92 (0.75-1.12) 0.78 (0.57-1.07) >0.2 
   Hazard ratios, model 1b 1.00 0.87 (0.70-1.07) 0.72 (0.52-1.00) 0.09 
   Hazard ratios, model 1c 1.00 0.85 (0.69-1.05) 0.76 (0.54-1.05) 0.13 
Stroke mortality      
   Number of deaths 143 44 23  
   Hazard ratios, model 1a 1.00 0.97 (0.69-1.37) 1.28 (0.82-1.98) >0.2 
   Hazard ratios, model 1b 1.00 0.97 (0.68-1.39) 1.23 (0.77-1.95) >0.2 
   Hazard ratios, model 1c 1.00 0.96 (0.67-1.37) 1.26 (0.79-2.00) >0.2 
aAdjusted for age, sex, and study year. 
bAdjusted for age, sex, study year, education, alcohol and tea consumption, and smoking status. 
cAdjusted for age, sex, study year, body mass index, systolic blood pressure, total cholesterol, education,  
alcohol and coffee consumption, and smoking status. 
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 6.        DISCUSSION 
6.1      Coffee consumption and risk of type 2 diabetes 
This study revealed clear evidence for an inverse and graded association between coffee 
consumption and type 2 diabetes (Studies I, III, IV). Habitual coffee drinkers, both middle aged 
men and women, in the highest category of coffee consumption had the least risk of developing 
diabetes. The expanded analyses in the studies III and IV (larger sample size & longer follow up 
period) observed the same finding as study I.  Based on the published data, the Finnish 
population drinks more coffee than other populations (World Resources Institute 2003), so siting 
enough power to determine the risk of type 2 diabetes at high levels of coffee consumption.  
       
6.1.1    Coffee consumption and potential diabetes risk factors  
Coffee, obesity, BMI, & type 2 diabetes It is well known that obesity is associated with impaired 
glucose tolerance and development of type 2 diabetes (Cairney and Wade 1998; WHO reports 
2000; 1994). Excess fat accumulation may lead to increased insulin resistance, thus development 
of type 2 diabetes is predictable (Lewis et al. 2002). Weight control by lifestyle intervention has 
resulted in improvement in insulin and glucose control in obese people (Finnish Diabetes 
Prevention Program Research Group 2002; Diabetes Prevention Group 2001; Ross et al. 2000). 
Greenberg et al. found that caffeinated and decaffeinated coffees were independently associated 
with weight loss, which may imply that both caffeine and noncaffeine compounds in coffee may 
help people decrease body weight (Greenberg et al. 2006; Greenberg et al. 2005). This idea is 
supported by the recent results of a larger prospective study, which found that increases in 
caffeine, coffee, and decaffeinated coffee intake were associated with smaller weight gains over a 
12-year period (Lopez-Garcia et al. 2006a). 
 
Coffee, physical activity, & type 2 diabetes Sedentary life style and physical inactivity have been 
shown to be associated with obesity (King et al. 2001) and on the opposite side physical activity 
prevents it. One of the major recommendations to obese or nonobese people at risk of developing 
type 2 diabetes would be to keep up their physical activity or to be more physically active. 
Although weight reduction can be achieved by controlled diet and energy intake, physical activity 
will help energy expenditure and secure weight loss maintenance (Borg et al. 2004). 
 
Coffee, alcohol consumption, & type 2 diabetes Alcohol consumption has been found to be 
associated with the risk of type 2 diabetes in some epidemiological studies (Howard et al. 2004). 
Moderate alcohol consumption appears to be associated with a reduced risk for diabetes, whereas 
some evidence suggests that heavy alcohol consumption may be associated with an increased risk 
(Djoussé et al. 2007; Howard et al. 2004). Therefore, the observed effect of coffee consumption 
on the risk of diabetes may be influenced by alcohol consumption. The present study, however, 
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 indicated that the inverse association between coffee consumption and the risk of type 2 diabetes 
persisted in both alcohol drinkers and non-drinkers. 
 
Coffee, type 2 diabetes, &  joint association with potential risk factors Study III evaluated in 
detail the joint association of coffee consumption and diabetes risk factors including physical 
activity, BMI, and alcohol consumption, on the risk of development of type 2 diabetes. The 
inverse and graded association between coffee consumption and the risk of type 2 diabetes was 
consistent in both men and women, in the subjects with any joint levels of physical activity and 
BMI, and in alcohol drinkers and non-drinkers. Particularly interesting was the finding that 
among obese and inactive people, coffee consumption halved the risk of type 2 diabetes. 
 
The type of the coffee and type 2 diabetes In a previous study on the Finnish population 
(Reunanen et al. 2003), no association between the coffee consumption and incidence of type 2 
diabetes was observed. One possible explanation for the different results is that at the time of 
their baseline survey, in 1973 and 1977, most Finnish individuals drank pot-boiled coffee. At the 
end of the 1960s, 75% of the Finnish population drank boiled coffee (Aro 1990) but by 1987 this 
proportion had decreased to 24%, although, 69% drank filtered coffee (Pietinen et al 1990). 
Although, however, we were able to determine the type of the coffee consumed in our surveys in 
1987, and 1992, there was no interaction effect between the type of coffee and amount of coffee 
on the risk of type 2 diabetes in either men or women. Nevertheless, a significant, almost 3-fold, 
increase occurred in the risk of diabetes among men who drank pot-boiled coffee compared to 
men who drank filtered coffee. 
 
Coffee consumption & type 2 diabetes in women The observed inverse association between coffee 
consumption and the risk of type 2 diabetes seems to be stronger in women than in men, although, the 
sex-interaction was not statistically significant. Previous studies have revealed that caffeine may be 
positively associated with plasma estrogen, plasma estradiol, and sex hormone-binding globulin 
levels and inversely related with testosterone among postmenopausal women (Nagata et al. 1998; 
Ferrini et al. 1996). In addition, phytoestrogens may have beneficial effects on patients with 
diabetes. The phytoestrogen content of coffee and effects of caffeine on the hormonal level may 
explain the effects of coffee on the risk of diabetes in women. Nevertheless, in most populations, 
the prevalence of type 2 diabetes is lower in pre-menopausal women than in men (DECODE 
Study Group 2003; Qiao et al. 2003).  
 
6.2      Coffee consumption and glycemic markers 
The major finding in study II was an inverse association between coffee consumption and several 
markers of “glycemia and diabetes”. Coffee consumption was associated with lower values of 
fasting glucose, 2-hour glucose and fasting insulin among non-diabetic subjects. Coffee 
consumption was significantly and inversely associated with impaired fasting glucose, impaired 
glucose regulation, and hyperinsulinemia among both men and women and with isolated 
57
 impaired glucose tolerance only among women. Nevertheless, the sex difference on the effect of 
coffee drinking on glycemia was not statistically significant.  
 
Our findings were consistent with the observed inverse association between habitual coffee 
consumption and postload glucose level in Dutch (van Dam et al. 2004), Japanese (Yamaji et al. 
2004) and Swedish (Agardh et al. 2004) populations. This data revealed that coffee may affect 
postload glucose as well as fasting glucose (preload) metabolism. Coffee consumption, however, 
was more strongly associated with decreased postload glucose concentrations than fasting plasma 
glucose. Postload glucose regulation is an important issue not only in the glucose metabolism and 
development of diabetes but also in the developing of the most serious complications in diabetic 
patients. This issue needs to be investigated in more detail at the intestinal, hepatic, and the 
peripheral delivery stages of the glucose metabolism. Because up to 30 minutes after the 
ingestion of the glucose load, the increase in plasma glucose concentration can be attributed 
solely to the increased delivery into the circulation as a result of increased intestinal absorption in 
response to the load. Once this has peaked, the peripheral metabolism of glucose (i.e. delivery 
into muscle and fat tissue in addition to hepatic glucose metabolism) will have a significant affect 
on overall plasma concentrations and thus, any differences seen cannot solely be attributed to the 
affects on absorption (Frayn 1996). 
 
Lower fasting insulin values and the lower risk of hyperinsulinemia among coffee consumers in 
this study may be interpreted as an improvement in insulin sensitivity by coffee consumption at 
the peripheral delivery stage of the glucose metabolism. The acute affects of caffeine on 
decreasing insulin sensitivity have also been reported (Keijzers et al. 2002). One may believe, 
however, that these affects might be modified during a long period of coffee consumption as it 
has already seen in cardiovascular effects (Denaro et al. 1991) and glucose metabolism may 
follow a different pattern among heavy and chronic coffee consumers. Also, the beneficial effects 
of the other components of the coffee other than caffeine, on insulin sensitivity should be 
considered. In a recent cross-sectional study, Ärnlöv et al. investigated the association between 
coffee consumption and both insulin sensitivity and insulin secretion. They determined the 
insulin sensitivity index by hyperinsulinemic euglycemic clamp and found that both coffee and 
tea consumption improved insulin sensitivity (Arnlov et al. 2004).  
Despite the relatively good correlation between the fasting plasma insulin and insulin sensitivity 
derived from the hyperinsulinemic euglycemic clamp, measures of fasting plasma insulin explain no 
more than 50% of the variability in insulin action seen in non-diabetic subjects (Yeni-Komshian et al. 
2002; Laakso 1992). This is because plasma insulin levels not only depend on insulin sensitivity, 
but also on a complex interplay between insulin secretion, distribution, and degradation 
(Ferrannini and Mari 1998). The measurement of plasma insulin concentration after an overnight 
fast, however, seems to be one of the most practical ways to give some estimate of insulin 
resistance from a clinical perspective (Haffner et al. 1992; Zavaroni et al. 1989; Despres et al. 
1996; Fontbonne et al. 1991) and very high plasma insulin values usually reflect the presence of 
insulin resistance. Low, or normal, insulin values are probably effective on postload glucose 
concentration. 
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 6.3      Potential mechanisms underlying the protective effects of coffee 
consumption on glycemic markers and type 2 diabetes 
 
 
Although the biological mechanism behind the inverse association between coffee consumption 
and the risk of type 2 diabetes is unknown, several putative mechanisms can be proposed. 
 
Coffee in its metabolic process Coffee contains many compounds, other than well-known 
caffeine, which may have the potential to influence glucose metabolism in each of its metabolic 
stages. One of the possible mechanisms is the intestinal stage inhibition or retardation of the 
action of -Glucosidase by chlorogenic acid. The inhibition of this enzyme is an effective 
approach to control hyperglycemia (Matsui et al. 2001). It has also been reported that chlorogenic 
acid inhibits glucose transporters (Na+ -dependent glucose transporter) at the same stage 
(Kobayashi et al. 2000).  In addition, coffee may also influence the secretion of gastrointestinal 
peptides such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), both 
are known for their glucose lowering effects (Meier et al. 2001; Nauck et al. 1993). At the 
hepatic stage reduced Glucose-6-phosphatase (Glc-6-Phase) hydrolysis or its inhibition by the 
chlorogenic acid may reduce plasma glucose output leading to reduced plasma glucose 
concentration (Andrade-Cetto et al. 2001; Arion et al. 1997; Youn et al. 1986; Newgard et al. 
1984).  
 
Caffeine and Energy Expenditure Caffeine has been found to increase the resting metabolic rate 
in both lean and obese individuals (Horton and Geissler 1996; Bracco et al. 1995; Astrup et al. 
1990). This thermogenic effect of caffeine may overcome the energy imbalance accompanied by 
unfavorable lifestyle and improve glucose homoeostasis. 
 
Coffee Consumption and Iron Stores Te mechanism of the observed inverse association between 
coffee consumption and diabetes might be, at least in part, due to the inhibition of iron absorption 
by polyphenol compounds present in coffee (Mascitelli et al. 2007). Higher body iron stores are 
associated with an increased risk for diabetes (Jiang et al. 2004); moreover the induction of iron 
deficiency in impaired glucose tolerant subjects has been shown to improve insulin sensitivity 
(Facchini and Saylor 2002). 
 
Further details on other possible mechanism have been discussed within the discussions of the 
individual studies. 
 
6.4      Coffee, GGT & type 2 diabetes 
Study IV evaluated the association between coffee consumption and type 2 diabetes, based on 
baseline GGT levels. Despite observing the same inverse association between coffee and type 2 
diabetes, the results were influenced by baseline GGT levels. At high GGT levels (75% 
percentile), coffee drinking was inversely associated with type 2 diabetes in women and both 
sexes combined, but this association was non-significant in men.  
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 Serum GGT level & type 2 diabetes: The strong association between the serum concentration of 
GGT and the risk for the development of impaired fasting glucose or type 2 diabetes has already 
been documented (Perry et al. 1998). Recent prospective studies showed that the risk of the 
metabolic syndrome and type 2 diabetes increases with increasing serum GGT level (Nakanishi et 
al. 2004; Lee et al. 2003a; Lee et al. 2003b; Nakanishi et al., 2003; Perry et al. 1998) and GGT 
has been suggested as an important risk indicator for developing type 2 diabetes. Despite the 
apparent relation between the GGT levels and alcohol intake (Sharper et al. 1985; Skinner et al. 
1984), the association between GGT concentration and type 2 diabetes has been found to be 
independent of alcohol intake (Lee et al. 2003a; Lee et al. 2003b). Also among subjects with high 
normal GGT levels, BMI, and age are strong risk factors for incident type 2 diabetes (Lee et al. 
2003a; Lee et al. 2003b). A previous study based on almost same study population as our present 
study revealed that a higher serum GGT concentration within normal ranges was directly 
associated with the increased risk of type 2 diabetes (Lee et al. 2004).  
Present analysis has now indicated that the risk of type 2 diabetes among people with high 
normal serum GGT levels is not necessarily increased, but actually decreased among habitual 
coffee consumers. 
 
Coffee consumption & serum GGT level: The relation between coffee consumption and GGT 
concentration, which has been studied previously (Kono et al. 1994; Casiglia et al. 1993; Nilssen 
et al. 1990), revealed an inverse association between coffee consumption and GGT level. The 
effects of regular daily coffee consumption on liver enzymes were studied in a large number of 
subjects from the general population by Casiglia et al. (1993). They found that in coffee drinkers, 
GGT and other liver enzymes (alkaline-amino transferase and alkaline phosphatase) were lower 
than in non-coffee-drinking subjects or in those consuming less than 3 cups daily. In addition, a 
study by Esposito et al. (2003) revealed that moderate coffee consumption significantly increased 
the plasma glutathione (GSH) level among healthy subjects. It is well known that with increasing 
GSH levels, GGT concentration decreases consequently (Zhang et al. 2005).   
 
Proposed underlying mechanism: Better knowledge of GGT and its important physiologic role 
in pathological conditions is necessary in order to explain our present findings. It is known that 
GGT is a plasma membrane enzyme facilitating the transport of extracellular GSH into most 
types of cells and that GSH is the major intracellular nonprotein thiol defence against free 
radicals (oxidative stress) (Karp et al. 2001; Kugelman et al. 1994). The accumulation of free 
radicals, elevated oxidative stress, leads to a raise of the GGT level in order to modify the 
existing oxidative stress by reproducing GSH. The γ-glutamyl cycle, involving GGT, is the major 
pathway by which cells utilize extracellular GSH for the de novo synthesis of intracellular GSH 
(Griffith et al. 1978). This is the main way that membrane GGT is protecting cells from oxidative 
stress (Karp et al. 2001). The elevation of GGT could be the expression of excess deposition of 
fat in the liver (hepatic steatosis), and/or may reflect inflammation (Malnik et al. 2003; 
Hotalamsligil et al. 2003; Marchesini et al. 2001). Both express the presence of oxidative stress 
and its major role in pathological conditions such as inflammation, malignant diseases, aging, 
cardiovascular disease (Droge et al., 2002), and in pathophysiology of diabetes (Rosen et al. 
2001; West et al. 2000; Haluzik et al. 2000). A decrease in antioxidant capacity has been 
observed in the plasma of diabetic patients (Rosen et al. 2001; Haluzik et al. 2000; Maxwell et al. 
1997; Jones et al. 1988) and evidence from a number of experimental studies revealed that the 
formation of free radicals and the presence of oxidative stress is a direct consequence of 
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 hyperglycemia (Ceriello et al 1999; Graier et al. 1996; Diedrich et al. 1994). So, we know that 
coffee contains many compounds which consequently may have the potential to influence the 
glucose metabolism process to prevent hyperglycemia and oxidative stress (Sections 2.2.2.1, 5.2).                        
 
Finally, increased GGT levels, for any reason, are related to excess oxidative stress and excessive 
oxidative stress may play a role in initiating the development of type 2 diabetes. Thus, the 
increasing frequency of the disease in people with high GGT levels may be expected (Lee et al. 
2003a). In our study, however, we found fewer cases of incident diabetes among habitual coffee 
consumers with high normal GGT levels indicating stronger protective effects of coffee at these 
levels. It may be interpreted that the antioxidant capacity of coffee may be more activated at a 
particular oxidative stress level at which it is helpful in preventing diabetes in subjects who are 
more susceptible to develop diabetes. A recent study by Ruhl et al., investigated the association 
of coffee and tea consumption on chronic liver diseases (Ruhl et al. 2005), supports these 
findings. They found a lower risk associated with higher levels of coffee and/or tea consumption 
only in persons who are at higher risk for liver disease from heavier alcohol intake, overweight, 
diabetes, or high iron saturation. These findings suggest hypotheses for future research. 
 
6.5      Coffee Consumption & CVD mortality among diabetic patients  
Our large prospective study found an inverse association between coffee consumption and the 
risk of total, CVD and CHD mortality among patients with type 2 diabetes. These associations 
were independent of age, BMI, systolic blood pressure, total cholesterol, physical activity, 
alcohol drinking, and smoking.  
 
Type 2 diabetes and CVD risk It is well known that types 2 diabetes is a potential risk factor for 
all-cause, CVD, and stroke mortality (Hu et al. 2005a; Hu et al. 2005b; DECODE Study Group 
2001; Wei M et al. 1998; Lehto et al. 1996). A dose-response relationship between level of the 
hyperglycaemia and both CVD deaths and all-cause mortality has been observed (Wei et al. 
1998).  
 
Coffee consumption and CVD risk The relation between coffee consumption and CVD has been 
extensively studied. Although coffee consumption has frequently been related to unhealthy 
lifestyle behavior, or in the other words well known CVD risk factors such as smoking and 
sedentary lifestyle, the relation of coffee consumption with development or progression of CVD 
has remained controversial. Most of the previous cohort studies found no evidence of any 
positive association between coffee consumption and risk of CHD (Willett et al. 1996; Kawachi 
et al. 1994; Greenland 1993; Myers and Basinski 1992) while a Scottish cohort study (Woodward 
M 1999) revealed that higher coffee consumption was associated with the lower risk of CVD 
only among men.  In a study of a Finnish cohort, Kleemola et al. observed a lower risk of 
nonfatal MI in men with higher coffee consumption (>7 cups/d) (Kleemola 2000). They also 
found a slight increase in CHD mortality in the same group. Some other, mostly case-control 
studies, found a positive association (Cornelis et al. 2006; Happonen et al. 2004). The most 
recent data from Iowa Women’s Health Study cohort (Andersen et al. 2006) revealed that 
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 consumption of 1-3 cups of coffee per day would be protective on total and CVD death. Two 
other large cohort studies (Lopez-Garcia et al. 2006b) revealed no adverse association between 
coffee consumption and risk of developing CHD.  
 
Coffee consumption & CVD risk factors The effects of coffee and caffeine on the certain risk 
factors for CVD, such as blood pressure and serum cholesterol, have also been reported. In a 
long-term prospective study, Klag et al. found that coffee drinking is associated with the small 
increase in blood pressure (Klag et al. 2002) and Hartley et al. found that modest doses of 
caffeine may increase blood pressure (Hartley et al. 2002). Another study by Winkelmayer et al. 
(2005), however, demonstrated that consumption of coffee in women is not associated with the 
increased the risk of developing hypertension. Coffee reportedly raises lipid parameters, 
however, it is clearly evidenced that filtered coffee is free of two cholesterol raising ingredients, 
Cafestol and Kahweol (Weusten-Van der Wouw et al. 1994). Moreover, the positive effect of 
chronic intake of caffeine on serum lipids has been reported (Du et al. 2005). Previously, we 
found a graded inverse association between coffee consumption and type 2 diabetes (Tuomilehto 
et al. 2004) and now this large cohort study established a reduced risk of total, CVD, and CHD 
mortality among type 2 diabetic patients who drank two or more cups of coffee daily. This 
association was relatively strong and not affected by the other confounding or effect modifying 
factors that were included in the analyses. After the adjustment for the other CVD potential risk 
factors, the result actually became somewhat stronger.  
 
Proposed underlying mechanism It has been suggested that oxidative stress is the common 
pathogenic factor leading to insulin resistance, -cell dysfunction, impaired glucose tolerance, 
and finally to type 2 diabetes (Ceriello and Motz 2004). Furthermore, this mechanism has been 
implicated as the underlying cause of both the macrovascular and microvascular complications 
associated with type 2 diabetes (Brownlee 2001; Rösen et al. 2001; Pieper and Gross 1998; 
Tesfamariam 1994). Blood glucose fluctuation during postprandial glycaemic excursions, in 
people with impaired glucose tolerance or type 2 diabetes, may significantly contribute to 
oxidative stress even more than chronic elevation of blood glucose (Hirsh and Brownlee 2005). 
Experimental studies demonstrate that the formation of free radicals and presence of oxidative 
stress is a direct consequences of hyperglycaemia (Graier et al. 1996; Diedrich et al. 1994; 
Tesfamariam et al. 1990) and postprandial hyperglycaemia is a significant predictor of CVD both 
in non-diabetic subjects and diabetic patients (The DECODE Study Group 2003; Qiao et al. 
2002; DECODE Study Group 2001).  
Thus, preventing hyperglycemia means protecting cells from further progression to diabetes and 
its complications. Previous studies, from diverse countries, revealed that higher coffee 
consumption was consistently associated with a lower prevalence of hyperglycemia and in 
particular, coffee consumption seems to lower post-prandial hyperglycemia (Van Dam et al. 
2004; Yamaji et al. 2004). We also found lower fasting insulin values and the lower risk of 
hyperinsulinemia among coffee consumers with long term exposure, which may consequently be 
interpreted as an improvement in insulin sensitivity by coffee consumption to prevent 
hyperglycemia and oxidative stress. It has been also suggested that coffee may interfere in 
different stages of glucose metabolism and glycemic regulation regarding preventing 
hyperglycemia (Bidel et al. 2006). 
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 6.6      Methodological considerations 
This study is based on the FINRISK database. Compared with other studies the FINRISK Study 
has many advantages, such as a large number of baseline measurements of risk factors and 
comprehensive follow-up data. It is carried out in a relatively homogeneous population. After the 
baseline data collections and examination, each subject has been followed by computerized 
record linkage using the unique national personal identification (PI) code assigned to every 
Finnish resident, to various national data bases. These include the Causes of Death Register 
(Statistics Finland), the National Hospital Discharge Registry (Stakes) since 1968, the National 
Social Insurance Institute’s (KELA) Drug register since 1964, and the National Cancer Registry 
since 1953. Thus, it would be possible to have a complete ascertainment of the subjects for the 
follow-up and obtain information about changes in their health status after the baseline 
examination.  
 
The results of these large prospective studies have extended the results of the other countries 
published during recent years. The prospective design, relatively long follow-up, and almost 
complete information on potential confounders are definite advantages of this study. Several 
issues regarding exposure classification, outcome measure, and residual confounding, however, 
should be considered when interpreting the results. 
  
Coffee exposure in this study is assessed using a questionnaire that collects information regarding 
the number of cups of coffee consumed daily. Since relying on self-reports, this study may be 
susceptible to bias resulting from inaccurate reporting. The misclassification of exposure, 
however, is most probably not systematically related to the outcome and vice versa. Therefore, it 
should not have caused biased results, but may only weaken the observed association.  
No information available from study questionnaire elicited the size of the coffee cup. It has been 
speculated, however, that the size of the coffee cup in Finland was approximately 100-125 ml at 
the time of the baseline data collections. Nevertheless, the test for trend did not depend on cup 
size, since coffee consumption was included as a continuous variable. Depending on the 
population the cup size may vary and it can not be standardized (Debry 1994). Thus, the caffeine 
content of coffee can vary and people who drink more may consume weaker coffee than people 
who drink only one or two cups per day. The type of coffee and the brewing methods to prepare 
coffee are other issues for which not much information is available. 
 
Validity of exposure measurement is a key problem in epidemiological research (Armstrong et al. 
1992). Based on the validation study of the dietary questionnaire carried out in subgroups of the 
study population, however, the correlations between the dietary questionnaire and food records 
for coffee were 0.89 in men and 0.85 in women (Paalanen et al. 2006). 
 
Differences in the metabolism of compounds in coffee may cause variation in the exposure for an 
individual. For instance, N-acetyltransferase 2 plays a significant role in the metabolism of 
caffeine (Carrillo and Benitez 2000). A polymorphism in N-acetyltransferase 2 gene may affect 
the individual exposure to the metabolites of caffeine (Nakajima et al. 1999; Sachse et al. 1999). 
In addition, it has been reported that cigarette smoking increases caffeine clearance by inducing 
the activity of the cytochrome P450 1A2 isoform, which accounts for 95% of the metabolism of 
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 caffeine, and thus the level of the caffeine in smokers is lower than that in nonsmokers given the 
same level of caffeine consumption (Joeres R et al., 1988). 
 
Avoiding drinking coffee due to a preexisting chronic disease may be a concern as a potential 
bias. We, however, excluded participants with reported diabetes, CHD, or stroke at baseline and 
this bias is unlikely to influence our results. 
 
A lack of the glucose tolerance test at baseline and follow-up surveys could have caused us to 
miss some cases of asymptomatic and diet-treated diabetes although the clinical diagnosis of 
diabetes from the hospital discharge register may in part avoid this potential under-diagnosis.  
With all precaution measures, however, it was possible that some of the diabetic subjects were 
among subjects who are classified as non-diabetic and it may became a source of bias in this 
study. To avoid this potential bias, additional analyses were performed excluding cases of type 2 
diabetes, which occurred during the first four years of follow up but the results did not change. 
 
Finally, the affects of residual confounding due to measurement error in the assessment of 
confounding factors, or some unmeasured factors including coffee additives (sugar and/or milk) 
and several dietary factors (such as the intake of the whole grain, the intake of fiber, magnesium, 
calcium, sodium, saturated and polyunsaturated fat, glycaemic load of the diet and total energy 
intake) can not completely be excluded (Hu et al. 2005c; Steyn et al. 2004; Song et al. 2004). 
 
6.7      Future prospects 
The potentially preventable nature of type 2 diabetes has been evidenced by the implementation 
of lifestyle measures, such as weight control and exercise. In many of the borderline cases of type 
2 diabetes, the clinical appearance of the disease and consequent complications may be delayed 
or prevented by diet and exercise for many years. It may show the efficacy of the dietary 
behavior in preventing or slowing the progression the disease. More or less, coffee has been 
included in the dietary menu of most of the people and it seems to be helpful in overall glucose 
metabolism. We believe, however, that these protective effects cannot be solely achieved by 
coffee drinking without considering the other lifestyle measures. In addition, many people stop or 
lessen coffee drinking due to aging, digestive problems, or some other health related reasons and 
consequently the overall incidental rates have not changed.  
 
Although habitual coffee consumption seems to be a safe and useful lifestyle behavior in type 2 
diabetes, which has been confirmed by published data from diverse countries, better knowledge 
of the components of the coffee, human consumption, and bioavailability is still needed in order 
to properly evaluate the true role of coffee in type 2 diabetes. Eventually, research in this area 
should lead to dietary recommendations optimized for specific population groups at risk of type 2 
diabetes. 
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 7.        CONCLUSIONS 
To our knowledge this is the first time that the relation between coffee and type 2 diabetes has 
been completely reviewed. These finding were based on large cohort studies with long term 
follow-up and cross-sectional studies.  
Following conclusions related to the study objectives were drawn based on the main findings: 
 
1. A strong and graded inverse relationship exists between coffee consumption and the risk of 
type 2 diabetes among Finnish men and women, a population with the highest coffee 
consumption in the world.  
Expansion of the analysis with a larger sample size and longer follow up period confirmed the 
previous results and this association was observed regardless of the levels of physical activity, 
BMI, and alcohol consumption. Among obese and inactive people drinking seven or more cups 
of coffee daily halved the risk of type 2 diabetes.  
 
2. In the cross-sectional analysis, we found that coffee has favorable affects on the markers of 
glycemia. An inverse association between coffee consumption and several markers of glycemia 
particularly fasting glucose, 2-hour glucose, and fasting insulin among non-diabetic subjects, was 
an extremely important finding.  
   
 3. The inverse association between coffee consumption and the incident type 2 diabetes is 
modified by serum GGT levels. The mechanism of this association has not yet been clarified. 
Nevertheless, the antioxidant activity of coffee by interfering in the glucose metabolism process 
is the most probable mode of action, since a high GGT level is a marker of oxidative stress. 
 
4. A consistent inverse relationship exists between coffee consumption and the risk of total, 
CVD, and CHD mortality among patients with type 2 diabetes. The complex components of 
coffee with antioxidant activity and potential to interfere in the different stages of glucose 
metabolism to control hyperglycemia are the most probable mechanisms. 
 
Final conclusion: These data will complement the gradually growing body of data that provides 
more evidence for the overall beneficial effects of coffee consumption in relation to type 2 
diabetes. 
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